US20090192493A1 - Implantable drug-delivery devices, and apparatus and methods for refilling the devices - Google Patents

Implantable drug-delivery devices, and apparatus and methods for refilling the devices Download PDF

Info

Publication number
US20090192493A1
US20090192493A1 US12/348,178 US34817809A US2009192493A1 US 20090192493 A1 US20090192493 A1 US 20090192493A1 US 34817809 A US34817809 A US 34817809A US 2009192493 A1 US2009192493 A1 US 2009192493A1
Authority
US
United States
Prior art keywords
needle
delivery device
drug
entry port
stop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/348,178
Inventor
Ellis Meng
Mark Humayun
Ronalee Lo
Po-Ying Li
Saloomeh Saati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Priority to US12/348,178 priority Critical patent/US20090192493A1/en
Assigned to UNIVERSITY OF SOUTHERN CALIFORNIA reassignment UNIVERSITY OF SOUTHERN CALIFORNIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUMAYUN, MARK, LI, PO-YING, LO, RONALEE, MENG, ELLIS, SAATI, SALOOMEH
Publication of US20090192493A1 publication Critical patent/US20090192493A1/en
Assigned to NATIONAL SCIENCE FOUNDATION reassignment NATIONAL SCIENCE FOUNDATION CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF SOUTHERN CALIFORNIA
Priority to US13/868,649 priority patent/US9901687B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/42Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
    • A61M5/427Locating point where body is to be pierced, e.g. vein location means using ultrasonic waves, injection site templates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/158Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/46Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A61M2005/14284Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation with needle insertion means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02Access sites
    • A61M39/0208Subcutaneous access sites for injecting or removing fluids
    • A61M2039/0238Subcutaneous access sites for injecting or removing fluids having means for locating the implanted device to insure proper injection, e.g. radio-emitter, protuberances, radio-opaque markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3507Communication with implanted devices, e.g. external control
    • A61M2205/3523Communication with implanted devices, e.g. external control using telemetric means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/582Means for facilitating use, e.g. by people with impaired vision by tactile feedback
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/60General characteristics of the apparatus with identification means
    • A61M2205/6054Magnetic identification systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/60General characteristics of the apparatus with identification means
    • A61M2205/6063Optical identification systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00Ancillary equipment
    • A61M2209/04Tools for specific apparatus
    • A61M2209/045Tools for specific apparatus for filling, e.g. for filling reservoirs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00Anatomical parts of the body
    • A61M2210/06Head
    • A61M2210/0612Eyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02Access sites
    • A61M39/0208Subcutaneous access sites for injecting or removing fluids

Definitions

  • the invention relates to implantable drug-delivery devices and to apparatus and methods for refilling such devices.
  • Medical treatment often requires the administration of a therapeutic agent (e.g., medicament, drugs, etc.) to a particular part of a patient's body.
  • a therapeutic agent e.g., medicament, drugs, etc.
  • Some maladies, however, are difficult to treat with currently available therapies and/or require administration of drugs to anatomical regions to which access is difficult to achieve.
  • a patient's eye is a prime example of a difficult-to-reach anatomical region, and many vision-threatening diseases, including retinitis pigmentosa, age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma, are difficult to treat with many of the currently available therapies.
  • AMD age-related macular degeneration
  • glaucoma a complex regional pain syndrome
  • oral medications can have systemic side effects; topical applications may sting and engender poor patient compliance; injections generally require a medical visit, can be painful, and risk infection; and sustained-release implants must typically be removed after their supply is exhausted.
  • cancer such as breast cancer or meningiomas
  • highly toxic chemotherapies such as rapamycin, bevacizumab (e.g., Avastin®), or irinotecan (CPT-11)
  • rapamycin e.g., rapamycin
  • bevacizumab e.g., Avastin®
  • irinotecan CPT-11
  • Implantable drug-delivery devices which may have a refillable drug reservoir, cannula, and check valve, etc., generally allow for controlled delivery of pharmaceutical solutions to a specified target. As drug within the drug reservoir depletes, the physician can refill the reservoir with, for example, a syringe, while leaving the device implanted within the patient's body.
  • the device can be damaged. Such damage may necessitate removal of the device and its replacement with another, thereby obviating some of the advantage of using the device. Even if the device is not damaged, insertion of the needle too far into the device can, for example, embed the needle tip in the bottom wall of the device's reservoir, thereby clogging the needle's lumen. Additionally, the improper insertion of the needle into the device may lead to the delivery of the drug into an improper location.
  • the present invention features apparatus and methods for refilling, in situ, a drug-delivery device implanted within a patient's body.
  • the apparatus generally contain features, and the methods typically contain steps, that allow the refilling to occur in a manner that minimizes the risk of damage to the device, and thereby maximizes its effective lifetime.
  • a refilling needle described herein employ a needle depth gauge to limit the degree to which the needle penetrates the drug-delivery device during a refilling procedure.
  • the drug-delivery device itself may include a stop to limit the extent of the needle's penetration therein.
  • embodiments of the invention employ a visualization ring that identifies the needle entry port.
  • embodiments of the invention feature a needle for refilling an implantable drug-delivery device.
  • the drug-delivery device may have a needle entry port that includes a throat for receiving the needle therethrough.
  • the needle may include a hollow shaft that terminates in a tip, a fluid exit port along the shaft proximate to the tip, and means for limiting the extent of entry of the needle into the entry port.
  • the needle tip is conically-shaped.
  • the fluid exit port of the needle may be positioned intermediate to the tip and the limitation means.
  • the limitation means includes a stop on the needle shaft.
  • the stop may be a ring surrounding and fixedly mounted to the shaft.
  • the ring may have an outer diameter exceeding a width of the entry port's throat.
  • the stop may be spherically-shaped, cylindrically-shaped, rectangularly-shaped, or pyramidally-shaped.
  • the limitation means is constructed of a metal, a plastic, and/or a composite material.
  • the limitation means may be, for example, constructed of a biocompatible material, such as polydimethylsiloxane (PDMS).
  • PDMS polydiorganosiloxane
  • PEEK polyetheretherketone
  • acetyl film polyoxymethylene plastic, gold, stainless steel, nickel, chrome, and combinations thereof.
  • inventions of the invention feature an implantable drug-delivery device.
  • the drug-delivery device includes a drug reservoir, a needle entry port, and a vestibule.
  • the needle entry port may include a throat for receiving a refill needle therethrough.
  • the throat may open into the vestibule, which may (i) be wider than the throat, (ii) include a stop on a wall opposite the throat for halting progress of a needle into the vestibule through the throat, and (iii) be in fluid communication with the drug reservoir.
  • the drug-delivery device also includes a check valve that is located between the vestibule and the drug reservoir.
  • the needle entry port may also include a self-sealing material (e.g., at its top surface).
  • the stop within the vestibule is sized so as to halt the progress of a needle that includes an exit port at a point at which the exit port is in fluid communication with the vestibule.
  • a top surface of the stop may be cup-shaped.
  • the stop is constructed of a metal, a plastic, and/or a composite material.
  • the stop may be, for example, constructed of a biocompatible material, such as PDMS.
  • Other exemplary materials from which the stop may be constructed include polyimide, polypropylene, PEEK, polycarbonate, an acetyl film, polyoxymethylene plastic, gold, stainless steel, nickel, chrome, and combinations thereof.
  • embodiments of the invention feature an implantable drug-delivery device that includes a drug reservoir, a needle entry port, and a visualization ring surrounding the needle entry port.
  • the needle entry port may include a throat for receiving a refill needle therethrough.
  • the throat may open into a vestibule that is in fluid communication with the drug reservoir.
  • the visualization ring may be visible through ocular tissue (e.g., a patient's conjunctiva) so as to visually indicate the position of the needle entry port.
  • the visualization ring is constructed of a material that is biocompatible and/or withstands penetration by the refill needle.
  • the visualization ring may include one or more fluorescent pigments, such as a luminescent aerogel, a nanoparticle, a phthalocyanine (PC) pigment, fluorescein isothiocyanate, rhodamine, coumarin, cyanine, an Alexa Fluor, a DyLight Fluor, a quantum dot, a green fluorescent protein, and/or a luciferin.
  • the visualization ring includes a light emitting diode.
  • a light emitting diode present in the drug-delivery device may be located away from the visualization ring and optical fiber may be used to conduct light from the light emitting diode to and around the visualization ring.
  • the visualization ring may also include a material that enhances surface echogenicity and acoustic shadowing. Electronics may also be present in the drug-delivery device in order to move or vibrate the visualization ring.
  • the visualization ring includes a magnetic material.
  • embodiments of the invention feature a method for refilling a drug-delivery device implanted within a patient.
  • the method includes inserting, into a needle entry port of the drug-delivery device, a distal tip of a needle that includes a hollow shaft and a stop on the shaft.
  • the needle may then be advanced into the needle entry port until the stop limits further entry of the needle into the entry port.
  • Drug may be delivered through the hollow shaft of the needle, out a fluid exit port positioned along the shaft of the needle proximate the tip, and into the drug-delivery device.
  • the stop may be a ring that surrounds the shaft of the needle and that has an outer diameter exceeding a width of the entry port.
  • embodiments of the invention feature another method for refilling a drug-delivery device implanted within a patient.
  • the method includes inserting, into a needle entry port of the drug-delivery device, a distal tip of a needle.
  • the needle may then be advanced through the needle entry port into a vestibule of the drug-delivery device until a stop positioned on a wall of the vestibule opposite the needle entry port halts further entry of the needle.
  • Drug may be delivered through a hollow shaft of the needle, out a fluid exit port positioned along the shaft of the needle proximate the tip, and into the vestibule.
  • the stop may halt further entry of the needle at a point at which the exit port of the needle is in fluid communication with the vestibule.
  • these methods include locating, prior to inserting the distal tip of the needle into the needle entry port, a visualization ring that visually indicates the position of the needle entry port.
  • the visualization ring may surround the needle entry port and be visible through the patient's conjunctiva.
  • FIG. 1 illustrates a plan view of an implantable drug-delivery device in accordance with one embodiment of the invention
  • FIG. 2 schematically illustrates the internal structure between a needle entry port and a drug reservoir in accordance with one embodiment of the invention
  • FIG. 3 is an elevation view of a refill needle in accordance with one embodiment of the invention.
  • FIG. 4 schematically illustrates a refill needle, having a stop fixedly mounted thereto, inserted within a portion of a drug-delivery device in accordance with one embodiment of the invention
  • FIG. 5 schematically illustrates a refill needle inserted within a portion of a drug-delivery device, having a stop fixedly mounted to one wall of a vestibule, in accordance with one embodiment of the invention
  • FIG. 6 is a sectional view of a patient's eye illustrating implantation therein of a drug-delivery device in accordance with one embodiment of the invention.
  • embodiments of the present invention pertain to drug-delivery devices implantable within a patient's body, such as, for example, within the patient's eye, and to apparatus and methods for refilling those devices.
  • an implantable drug-delivery device combines small size and a refillable reservoir. The small size minimizes discomfort from the device to the patient, while the refillable reservoir allows the device to be refilled in situ, rather than being replaced.
  • a fluid such as a solution of a drug, can be supplied to the patient over extended periods of time.
  • FIG. 1 schematically illustrates an exemplary implantable drug-delivery device 100 .
  • the exemplary device 100 includes a base 104 , a refillable drug reservoir 108 , a drug-delivery cannula 112 in fluid communication with the refillable drug-reservoir 108 , and a needle entry port 116 in fluid communication with the refillable drug reservoir 108 as further described below.
  • the refillable drug reservoir 108 holds the therapeutic fluid to be delivered, while the cannula 112 directs the fluid to the targeted site.
  • the cannula 112 may be tapered to facilitate its insertion into, for example, a patient's eye.
  • the drug reservoir 108 can be refilled by inserting a refill needle 120 into and through the needle entry port 116 .
  • the drug-delivery device 100 may be mechanically (e.g., manually) or electrolytically actuated to deliver the therapeutic fluid to a targeted site.
  • FIG. 2 schematically illustrates the internal structure of the drug-delivery device 100 between the needle entry port 116 and the drug reservoir 108 in accordance with one embodiment of the invention.
  • the needle entry port 116 includes a surface 124 and a throat 128 for receiving the refill needle 120 therethrough.
  • the throat 128 opens into a vestibule 132 that is in fluid communication (through, for example, a check valve 136 ) with the drug reservoir 108 .
  • the refill needle 120 pierces, as depicted, the surface 124 of the needle entry port 116 , travels through its throat 128 , and thereby gains access to the vestibule 132 .
  • injection of a therapeutic fluid from the needle 120 into the vestibule 132 forces the fluid through the check valve 136 and into the reservoir 108 , thereby refilling the reservoir 108 .
  • a visualization ring 140 may surround the needle entry port 116 of the implantable drug-delivery device 100 .
  • the visualization ring 140 is made of a material or pigment that is visible through ocular tissue (e.g., through a patient's conjunctiva) so as to visually indicate a position of the needle entry port 116 to a user of the device 100 (e.g., a physician) when the device 100 is implanted within a patient's eye.
  • the material or pigment forming the visualization ring 140 may be biocompatible and/or able to withstand penetration by the refill needle 120 if and when the refill needle 120 is accidently placed in contact therewith.
  • Exemplary materials from which the visualization ring 140 may be constructed include, but are not limited to, PDMS, polyimide, PEEK, gold, stainless steel, and titanium.
  • the material or pigment forming the visualization ring 140 may optionally fluoresce when exposed to a particular type of light, such as ultraviolet (UV) light.
  • UV light ultraviolet
  • fluorescent pigments In daylight, fluorescent pigments have a white or light color and are therefore generally cosmetically invisible. Under excitation by UV radiation, however, the fluorescent pigments typically irradiate an intensive fluorescent color.
  • Exemplary pigments that may form the visualization ring 140 include, but are not limited to, luminescent aerogels, nanoparticles (e.g., silicon nanoparticles), phthalocyanine (PC) pigments, fluorescein isothiocyanate, rhodamine (TRITC), coumarin, cyanine, Alexa Fluors, DyLight Fluors, quantum dots, green fluorescent proteins, and/or luciferins.
  • the visualization ring 140 and its substrates may generally be cosmetically invisible until such time as the physician exposes the ring 140 to UV light. At that point, the physician can easily visualize the ring 140 , either visually or with the aid of, for example, a fluorescence stereo microscope.
  • the visualization ring 140 may also be made with materials that enhance surface echogenicity and acoustic shadowing so that the physician may better visualize the needle entry port 116 when using certain imaging devices.
  • materials include metals, semiconductors, and advanced composite materials that cause the visualization ring 140 to become more reflective or absorbent to ultrasound waves or infrared light (in contrast to the other materials on the non-ring portions of the drug-delivery device 100 that are not desired to be visualized) during such times as when the physician uses an ultrasound scanner, an optical coherence tomography (OCT) visualization tool, or other coherence scanner for visualizing the ring 140 subcutaneously.
  • OCT optical coherence tomography
  • the visualization ring 140 will be more easily visualized by the physician when using an OCT scanner or ultrasound scanner since the light, laser, or sound will be reflected differently by the gold.
  • the visualization ring 140 includes one or more light emitting diodes (LEDs) that illuminate during the desired time of refilling.
  • the drug-delivery device 100 may include an internal power supply (e.g., a battery) and other electronics to supply power to the LEDs. Then, the physician may activate the power supply and electronics wirelessly (e.g., using a device that emits a radio-frequency (RF) signal) to turn the LEDs on just prior to refilling the drug-delivery device 100 .
  • RF radio-frequency
  • the LEDs may be located in a different part of the drug-delivery device 100 (e.g., distant from the visualization ring 140 ) and a conduit, such as a bundle of optical fiber, may be used to conduct the light from the LEDs to the visualization ring 140 and also around the visualization ring 140 .
  • the visualization ring 140 and/or the needle entry port 116 moves up and down, or vibrates, in a manner that gives the physician a tactile sensation confirming the location of the visualization ring 140 and/or needle entry port 116 .
  • movement and/or vibration may be imparted to the visualization ring 140 and/or the needle entry port 116 through the use of electronics internal to the drug-delivery device 100 .
  • Those electronics may be activated remotely through, for example, a handheld device emitting an RF signal.
  • the visualization ring 140 includes a magnetic material.
  • the visualization ring 140 may be made, at least in part, from a ferromagnetic material alone, or it may include a ferromagnetic material encased in a ceramic.
  • the refill needle 120 used in combination with such a visualization ring 140 may likewise contain magnetic materials, for example on a tip 208 and/or shaft 212 thereof, and/or on a stop 224 connected thereto (see FIG. 3 ). In this way, the magnetic materials of the visualization ring 140 may attract the magnetic materials of the refill needle 120 , thereby aiding the physician in locating the needle entry port 116 .
  • the magnetic materials of the visualization ring 140 and the refill needle 120 may aid in aligning the shaft 212 of the refill needle 120 with the elongate axes of the throat 128 and vestibule 132 , thereby preventing the needle 120 from contacting (and potentially puncturing) a sidewall 144 of the vestibule 132 .
  • the needle entry port 116 may be very small, and the physician may be injecting drugs in an invasive manner, it is often useful to add a secondary or tertiary confirmatory signal for the location of the visualization ring 140 and the needle entry port 116 , such as sight, sound, tactile sensation, and/or magnetic interaction.
  • the visualization ring 140 is embedded into (and thus completely surrounded by) the material forming the surface 124 of the needle entry port 116 .
  • the visualization ring 140 does not come into contact with the patient's body or with any medications delivered to the device 100 by the refill needle 120 .
  • this is important.
  • the use of some materials in the visualization ring 140 such as rhodamine pigments, can be toxic to the patient's body or degrade over time if not properly sealed with the material forming the surface 124 .
  • the visualization ring 140 may be an annulus and, as illustrated in FIG. 2 , its inner diameter may define the width w 1 of the throat 128 through which the refill needle 120 passes when it is inserted into the needle entry port 116 . Moreover, in one embodiment, the width w 2 of the vestibule 132 is greater than the width w 1 of the throat 128 . In this way, the smaller width w 1 of the throat 128 constrains the movement of the refill needle 120 as it is advanced into the vestibule 132 and aids in preventing the needle 120 from contacting (and potentially puncturing) the sidewall 144 of the vestibule 132 .
  • an insertion guider may be positioned at a top surface of, or within, the needle entry port 116 to aid in guiding the refill needle 120 along the elongate axis of the vestibule 132 (and not into the sidewall 144 ).
  • the insertion guider may be cylindrical in shape, or have another shape.
  • the insertion guider may be removable and may be placed on top of the needle entry port 116 and mechanically or magnetically locked to the needle entry port 116 just prior to the refilling procedure.
  • the material of the surface 124 is self-sealing. More specifically, the surface 124 may be formed from a soft plastic material that can be punctured with the needle 120 and that reseals itself upon removal of the needle 120 . In one embodiment, the self-sealing material is able to withstand multiple punctures by the needle 120 , and is biocompatible.
  • Examples of materials that may be employed for the self-sealing material include, but are not limited to, PDMS, parylene C, parylene HT, polycarbonates, polyolefins, polyurethanes, copolymers of acrylonitrile, copolymers of polyvinyl chloride, polyamides, polysulphones, polystyrenes, polyvinyl fluorides, polyvinyl alcohols, polyvinyl esters, polyvinyl butyrate, polyvinyl acetate, polyvinylidene chlorides, polyvinylidene fluorides, polyimides, polyisoprene, polyisobutylene, polybutadiene, polyethylene, polyethers, polytetrafluoroethylene, polychloroethers, polymethylmethacrylate, polybutylmethacrylate, polyvinyl acetate, nylons, cellulose, gelatin, silicone rubbers and porous rubbers.
  • the self-sealing material includes
  • FIG. 3 depicts one embodiment of the refill needle 120 .
  • the refill needle 120 includes a proximal end 200 (i.e., an end closest to an operator of the refill needle 120 ) and an opposite, distal end 204 .
  • the distal end 204 of the needle 120 terminates in a tip 208 , such as a conically-shaped tip.
  • the tip 208 may, of course, have another shape suitable for piercing the surface 124 of the needle entry port 116 .
  • the distal end 204 of the refill needle 120 may be cut (or otherwise formed) at an oblique angle to form an oblique tip 208 .
  • a hollow shaft 212 extends from the proximal end 200 of the refill needle 120 to a proximal end 216 of the tip 208 .
  • the refill needle 120 may include at least one fluid exit port 220 positioned along the shaft 212 (e.g., near the tip 208 ).
  • the refill needle 120 may include, near the proximal end 216 of the tip 208 , two fluid exit ports 220 positioned approximately 180° apart around the circumference of the shaft 212 .
  • the fluid exit port(s) 220 may be positioned elsewhere along the shaft 212 .
  • the fluid exit port(s) 220 is/are in fluid communication with the lumen of the hollow shaft 212 .
  • therapeutic fluid may be passed through the hollow shaft 212 of the needle 120 , out its fluid exit port(s) 220 , and into the vestibule 132 .
  • the fluid exit port(s) 220 are generally oriented transverse to the long axis of the refill needle 120 . In this fashion, the refill needle 120 may be inserted into the needle entry port 116 of the device 100 with reduced risk of occluding the exit port(s) 220 with material cored from the walls of the throat 128 .
  • the refill needle 120 may also include a means for limiting an extent of entry of the needle 120 into the needle entry port 116 .
  • the limitation means may be a stop 224 fixedly mounted to the needle shaft 212 .
  • the stop 224 may be mounted to the shaft 212 at a point proximal to the fluid exit port(s) 220 , such that the fluid exit port(s) 220 is/are positioned intermediate to the needle tip 208 and the stop 224 .
  • the fluid exit port(s) 220 will be correctly positioned within the vestibule 132 of the device 100 when the stop 224 abuts the surface 124 of the needle entry port 116 , and the tip 208 at the distal end 204 of the needle 120 will not contact (or pierce) the bottom wall 148 of the vestibule 132 .
  • the stop 224 is positioned at a distance from the fluid exit port(s) 120 that is greater than the height h 1 of the throat 128 of the needle entry port 116 , and also at a distance from the distal end 204 of the refill needle 120 that is less than the combined height h 2 of the throat 128 and vestibule 132 . In this way, the stop 224 decreases the likelihood of the refill needle 220 penetrating the entire drug-delivery device 100 and entering, for example, the patient's eye.
  • the stop 224 also prevents the tip 208 of the refill needle 120 from becoming embedded in the bottom wall 148 of the vestibule 132 , where the fluid exit port(s) 220 and lumen of the needle 120 may be occluded, thereby preventing therapeutic fluid from being dispensed into the vestibule 132 .
  • the stop 224 is a ring that surrounds the shaft 212 of the refill needle 120 . So that the stop 224 halts the progress of the refill needle 120 into the vestibule 132 of the device 100 (i.e., limits the depth to which the refill needle 120 can be inserted into the vestibule 132 ), the ring, in one embodiment, has an outer diameter d 1 that exceeds the width w 1 of the throat 128 . In this way, the stop 224 and the portion of the refill needle 120 proximate to the stop 224 are prevented from entering the needle entry port 116 .
  • the outer contour of the stop 224 need not take the form of a ring.
  • the stop 224 may have an outer shape that is generally spherical, cylindrical, rectangular, or pyramidal, or may be shaped in another manner suitable for carrying out the functions of the stop 224 described herein.
  • the stop 224 may be constructed of a metal, a plastic, a composite material, or a combination thereof.
  • the metal, plastic, and/or composite material may be biocompatible, or not.
  • the stop 224 is constructed of PDMS.
  • the stop 224 may be constructed of other material, or combinations of materials, that have the requisite mechanical strength to perform the function of the stop 224 described herein.
  • the stop 224 may also be constructed of polyimide, polypropylene, PEEK, polycarbonate, acetyl film (e.g., acetyl copolymer), polyoxymethylene plastic (e.g., Delrin®), gold, stainless steel, nickel, and/or chrome.
  • the stop 224 may also take the form of an integral, disk-like protrusion from (and extending around) the needle shaft 212 , introduced during the manufacture thereof.
  • an exemplary refill needle 120 may be prepared by pinching closed a hollow 30-gauge needle and deburring the closure to leave a conical tip 208 of approximately 254 ⁇ m in height.
  • Two exit ports 220 each measuring approximately 101 ⁇ m in diameter, may then drilled through refill needle 120 approximately 127 ⁇ m above the proximal end 216 of the conical tip 208 .
  • a stop 224 may then be fabricated by laser-cutting a thin PDMS membrane into an appropriately sized ring shape.
  • the inner diameter of the ring-shaped stop 224 is determined by the size of the outer diameter of the refill needle 120 (i.e., approximately 305 ⁇ m for a 30-gauge needle).
  • the PDMS ring-shaped stop 224 may then be fitted onto the shaft 212 of the needle 120 and secured by, for example, a glue. The location on the shaft 212 to which the ring-shaped stop 224 is secured is chosen as described above.
  • a stop may be positioned within the vestibule 132 of the drug-delivery device 100 itself.
  • a stop 152 may be secured to, and caused to extend from, the bottom wall 148 of the vestibule 132 (i.e., a wall of the vestibule 132 opposite the throat 128 ), for example by gluing the stop 152 to the wall 148 . In this way, the progress of the refill needle 120 into the vestibule 132 through the throat 128 halts when the tip 208 of the needle 120 contacts the stop 152 .
  • the stop 152 may be sized (i.e., in height), and the fluid exit port(s) 220 placed on the shaft 212 of the refill needle 120 , so that the progress of the needle 120 into the vestibule 132 is halted at a point at which the exit port(s) 220 is/are in fluid communication with the vestibule 132 .
  • the stop 152 may be a rectangular prism, a cylinder, or any other shape suitable for carrying out the functions of the stop 152 described herein. As illustrated in FIG. 5 , a top surface 160 of the stop 152 may be flat. Alternatively, the stop 152 may be shaped as a cup (e.g., the top surface 160 of the stop 152 may be cup-shaped or concave). In this way, the stop 152 may also aid in preventing the refill needle 120 from contacting, and possibly penetrating, the sidewall 144 of the vestibule 132 .
  • the stop 152 may be constructed of a metal, a hard (e.g., fully cross-linked or reinforced) plastic, a composite material, or a combination thereof.
  • the stop 152 may be constructed from a thick layer of PDMS (i.e., a thicker layer than that used for the puncturable surface 124 of the needle entry port 116 ), polyimide, polypropylene, PEEK, polycarbonate, acetyl film (e.g., acetyl copolymer), polyoxymethylene plastic (e.g., Delrin®), gold, stainless steel, nickel, and/or chrome.
  • the stop 152 may be biocompatible, or not.
  • the stop 152 may be constructed of any relatively rigid and mechanically robust material, or combinations of materials, that have the requisite mechanical strength for performing the functions of the stop 152 described herein.
  • FIG. 6 schematically illustrates the exemplary drug-delivery device 100 implanted in the eye of a patient in accordance with one embodiment of the invention.
  • the device 100 is placed upon the conjunctiva of the eye, and the cannula 112 is inserted therethrough in to the posterior chamber of the eye.
  • the drug-delivery device 100 administers therapeutic fluid to the posterior chamber of the eye through the cannula 112 and a check valve 156 , which may control the delivery of the fluid and prevent backflow.
  • the device 100 is used to administer fluid to the anterior chamber of the eye, which is separated from the posterior chamber by the lens.
  • An operator of the drug-delivery device 100 may refill the device 100 in situ (i.e., without having to remove the device 100 from the patient's eye). To do so, in one embodiment, the operator first locates the visualization ring 140 of the device 100 .
  • the operator may locate the visualization ring 140 by simple visual inspection because, as described above, the visualization ring 140 is constructed of a material that is visible through the patient's conjunctiva. Moreover, because the visualization ring 140 surrounds the needle entry port 116 , it visually indicates the position of that needle entry port 116 to the operator.
  • the operator inserts the distal tip 208 of the refill needle 120 into the needle entry port 116 of the drug-delivery device 100 . More specifically, the operator may contact the surface 124 of the needle entry port 116 with the distal tip 208 of the refill needle 120 , pierce the surface 124 by advancing the needle 120 , and further advance the needle 120 into the throat 128 and then the vestibule 132 of the drug-delivery device 100 .
  • the operator may continue to advance the needle 120 into the needle entry port 116 until the stop 224 contacts the surface 124 of the needle entry port 116 , thereby limiting further entry of the needle 120 into the needle entry port 116 .
  • the vestibule 132 includes the stop 152 fixedly mounted to its bottom wall 148 , the operator may continue to advance the refill needle 120 into the needle entry port 116 until the distal tip 208 of the needle 120 contacts the stop 152 , which then halts further entry of the needle 120 into the vestibule 132 .
  • the operator will be assured, as described above, that the exit port(s) 220 of the refill needle 120 is/are properly placed within the vestibule 132 and in fluid communication therewith.
  • the operator may then cause a therapeutic fluid (e.g., a drug in liquid form) to be delivered through the hollow shaft 212 of the refill needle 120 , out the fluid exit port(s) 220 , and into the vestibule 132 of the drug-delivery device 100 .
  • a therapeutic fluid e.g., a drug in liquid form
  • the operator may rapidly refill the drug-delivery device 100 in situ, while the risk of damage to the device 100 and injury to the patient are also minimized.
  • the drug-delivery device 100 may also be implanted in other portions of a patient's body, such as in the sub-arachnoid space of the brain to provide chemotherapy or to provide another type of treatment for the brain, near a tumor in any portion of the patient's body to provide chemotherapy, or in a pancreas that does not respond well to glucose to provide agents (e.g., proteins, viral vectors, etc.) that will trigger insulin release.
  • agents e.g., proteins, viral vectors, etc.

Abstract

In various embodiments, a needle is employed in refilling drug-delivery devices.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims priority to and the benefit of, and incorporates herein by reference in its entirety, U.S. Provisional Patent Application No. 61/018,747, which was filed on Jan. 3, 2008.
  • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant Nos. ERC EEC-0310723 and EEC-0547544 awarded by the National Science Foundation.
  • TECHNICAL FIELD
  • In various embodiments, the invention relates to implantable drug-delivery devices and to apparatus and methods for refilling such devices.
  • BACKGROUND
  • Medical treatment often requires the administration of a therapeutic agent (e.g., medicament, drugs, etc.) to a particular part of a patient's body. Some maladies, however, are difficult to treat with currently available therapies and/or require administration of drugs to anatomical regions to which access is difficult to achieve.
  • A patient's eye is a prime example of a difficult-to-reach anatomical region, and many vision-threatening diseases, including retinitis pigmentosa, age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma, are difficult to treat with many of the currently available therapies. For example, oral medications can have systemic side effects; topical applications may sting and engender poor patient compliance; injections generally require a medical visit, can be painful, and risk infection; and sustained-release implants must typically be removed after their supply is exhausted.
  • Another example is cancer, such as breast cancer or meningiomas, where large doses of highly toxic chemotherapies, such as rapamycin, bevacizumab (e.g., Avastin®), or irinotecan (CPT-11), are typically administered to the patient intravenously, which may result in numerous undesired side effects outside the targeted area.
  • Implantable drug-delivery devices, which may have a refillable drug reservoir, cannula, and check valve, etc., generally allow for controlled delivery of pharmaceutical solutions to a specified target. As drug within the drug reservoir depletes, the physician can refill the reservoir with, for example, a syringe, while leaving the device implanted within the patient's body.
  • If, however, the syringe needle is inadvertently inserted too far into the device during the refilling, the device can be damaged. Such damage may necessitate removal of the device and its replacement with another, thereby obviating some of the advantage of using the device. Even if the device is not damaged, insertion of the needle too far into the device can, for example, embed the needle tip in the bottom wall of the device's reservoir, thereby clogging the needle's lumen. Additionally, the improper insertion of the needle into the device may lead to the delivery of the drug into an improper location.
  • A need exists, therefore, for improved implantable drug-delivery devices, and apparatus and methods for refilling such devices.
  • SUMMARY OF THE INVENTION
  • In various embodiments, the present invention features apparatus and methods for refilling, in situ, a drug-delivery device implanted within a patient's body. The apparatus generally contain features, and the methods typically contain steps, that allow the refilling to occur in a manner that minimizes the risk of damage to the device, and thereby maximizes its effective lifetime. For example, embodiments of a refilling needle described herein employ a needle depth gauge to limit the degree to which the needle penetrates the drug-delivery device during a refilling procedure. As another example, the drug-delivery device itself may include a stop to limit the extent of the needle's penetration therein. Moreover, to aid a physician in locating a needle entry port of the drug-delivery device, and to protect the patient from inadvertent punctures by the needle, embodiments of the invention employ a visualization ring that identifies the needle entry port. These features, together with others, facilitate the rapid refilling of the drug-delivery device, while minimizing the risk of damage to the device and injury to the patient. Thus, the time spent by a physician in refilling the drug-delivery device is reduced (which may generate a cost savings), the useful life of the drug-delivery device may be lengthened, and the need to replace drug-delivery devices damaged during the course of attempts to refill them is reduced.
  • In general, in one aspect, embodiments of the invention feature a needle for refilling an implantable drug-delivery device. The drug-delivery device may have a needle entry port that includes a throat for receiving the needle therethrough. For its part, the needle may include a hollow shaft that terminates in a tip, a fluid exit port along the shaft proximate to the tip, and means for limiting the extent of entry of the needle into the entry port. In one embodiment, the needle tip is conically-shaped. The fluid exit port of the needle may be positioned intermediate to the tip and the limitation means.
  • In various embodiments, the limitation means includes a stop on the needle shaft. For example, the stop may be a ring surrounding and fixedly mounted to the shaft. The ring may have an outer diameter exceeding a width of the entry port's throat. Alternatively, the stop may be spherically-shaped, cylindrically-shaped, rectangularly-shaped, or pyramidally-shaped. In certain embodiments, the limitation means is constructed of a metal, a plastic, and/or a composite material. The limitation means may be, for example, constructed of a biocompatible material, such as polydimethylsiloxane (PDMS). (Although the ensuing discussion refers primarily to PDMS, this is for convenience, and references to PDMS are intended to connote any suitably biocompatible form of polydiorganosiloxane (i.e., silicone) polymer.) Other exemplary materials from which the limitation means may be constructed include polyimide, polypropylene, polyetheretherketone (PEEK), polycarbonate, an acetyl film, polyoxymethylene plastic, gold, stainless steel, nickel, chrome, and combinations thereof.
  • In general, in another aspect, embodiments of the invention feature an implantable drug-delivery device. The drug-delivery device includes a drug reservoir, a needle entry port, and a vestibule. The needle entry port may include a throat for receiving a refill needle therethrough. The throat may open into the vestibule, which may (i) be wider than the throat, (ii) include a stop on a wall opposite the throat for halting progress of a needle into the vestibule through the throat, and (iii) be in fluid communication with the drug reservoir.
  • In various embodiments, the drug-delivery device also includes a check valve that is located between the vestibule and the drug reservoir. For its part, the needle entry port may also include a self-sealing material (e.g., at its top surface). In one embodiment, the stop within the vestibule is sized so as to halt the progress of a needle that includes an exit port at a point at which the exit port is in fluid communication with the vestibule. A top surface of the stop may be cup-shaped. In certain embodiments, the stop is constructed of a metal, a plastic, and/or a composite material. The stop may be, for example, constructed of a biocompatible material, such as PDMS. Other exemplary materials from which the stop may be constructed include polyimide, polypropylene, PEEK, polycarbonate, an acetyl film, polyoxymethylene plastic, gold, stainless steel, nickel, chrome, and combinations thereof.
  • In general, in yet another aspect, embodiments of the invention feature an implantable drug-delivery device that includes a drug reservoir, a needle entry port, and a visualization ring surrounding the needle entry port. The needle entry port may include a throat for receiving a refill needle therethrough. The throat may open into a vestibule that is in fluid communication with the drug reservoir. For its part, the visualization ring may be visible through ocular tissue (e.g., a patient's conjunctiva) so as to visually indicate the position of the needle entry port.
  • In various embodiments, the visualization ring is constructed of a material that is biocompatible and/or withstands penetration by the refill needle. The visualization ring may include one or more fluorescent pigments, such as a luminescent aerogel, a nanoparticle, a phthalocyanine (PC) pigment, fluorescein isothiocyanate, rhodamine, coumarin, cyanine, an Alexa Fluor, a DyLight Fluor, a quantum dot, a green fluorescent protein, and/or a luciferin. In another embodiment, the visualization ring includes a light emitting diode. Alternatively, a light emitting diode present in the drug-delivery device may be located away from the visualization ring and optical fiber may be used to conduct light from the light emitting diode to and around the visualization ring. The visualization ring may also include a material that enhances surface echogenicity and acoustic shadowing. Electronics may also be present in the drug-delivery device in order to move or vibrate the visualization ring. In yet another embodiment, the visualization ring includes a magnetic material.
  • In general, in still another aspect, embodiments of the invention feature a method for refilling a drug-delivery device implanted within a patient. The method includes inserting, into a needle entry port of the drug-delivery device, a distal tip of a needle that includes a hollow shaft and a stop on the shaft. The needle may then be advanced into the needle entry port until the stop limits further entry of the needle into the entry port. Drug may be delivered through the hollow shaft of the needle, out a fluid exit port positioned along the shaft of the needle proximate the tip, and into the drug-delivery device. In accordance with this method, the stop may be a ring that surrounds the shaft of the needle and that has an outer diameter exceeding a width of the entry port.
  • In general, in a further aspect, embodiments of the invention feature another method for refilling a drug-delivery device implanted within a patient. The method includes inserting, into a needle entry port of the drug-delivery device, a distal tip of a needle. The needle may then be advanced through the needle entry port into a vestibule of the drug-delivery device until a stop positioned on a wall of the vestibule opposite the needle entry port halts further entry of the needle. Drug may be delivered through a hollow shaft of the needle, out a fluid exit port positioned along the shaft of the needle proximate the tip, and into the vestibule. The stop may halt further entry of the needle at a point at which the exit port of the needle is in fluid communication with the vestibule.
  • In various embodiments, these methods include locating, prior to inserting the distal tip of the needle into the needle entry port, a visualization ring that visually indicates the position of the needle entry port. The visualization ring may surround the needle entry port and be visible through the patient's conjunctiva.
  • These and other objects, along with advantages and features of the embodiments of the present invention herein disclosed, will become more apparent through reference to the following description, the accompanying drawings, and the claims. Furthermore, it is to be understood that the features of the various embodiments described herein are not mutually exclusive and can exist in various combinations and permutations.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • In the drawings, like reference characters generally refer to the same parts throughout the different views. Also, the drawings are not necessarily to scale, emphasis instead generally being placed upon illustrating the principles of the invention. In the following description, various embodiments of the present invention are described with reference to the following drawings, in which:
  • FIG. 1 illustrates a plan view of an implantable drug-delivery device in accordance with one embodiment of the invention;
  • FIG. 2 schematically illustrates the internal structure between a needle entry port and a drug reservoir in accordance with one embodiment of the invention;
  • FIG. 3 is an elevation view of a refill needle in accordance with one embodiment of the invention;
  • FIG. 4 schematically illustrates a refill needle, having a stop fixedly mounted thereto, inserted within a portion of a drug-delivery device in accordance with one embodiment of the invention;
  • FIG. 5 schematically illustrates a refill needle inserted within a portion of a drug-delivery device, having a stop fixedly mounted to one wall of a vestibule, in accordance with one embodiment of the invention; and
  • FIG. 6 is a sectional view of a patient's eye illustrating implantation therein of a drug-delivery device in accordance with one embodiment of the invention.
  • DESCRIPTION
  • In general, embodiments of the present invention pertain to drug-delivery devices implantable within a patient's body, such as, for example, within the patient's eye, and to apparatus and methods for refilling those devices. In certain embodiments, an implantable drug-delivery device combines small size and a refillable reservoir. The small size minimizes discomfort from the device to the patient, while the refillable reservoir allows the device to be refilled in situ, rather than being replaced. As such, a fluid, such as a solution of a drug, can be supplied to the patient over extended periods of time.
  • FIG. 1 schematically illustrates an exemplary implantable drug-delivery device 100. The exemplary device 100 includes a base 104, a refillable drug reservoir 108, a drug-delivery cannula 112 in fluid communication with the refillable drug-reservoir 108, and a needle entry port 116 in fluid communication with the refillable drug reservoir 108 as further described below. In general, the refillable drug reservoir 108 holds the therapeutic fluid to be delivered, while the cannula 112 directs the fluid to the targeted site. The cannula 112 may be tapered to facilitate its insertion into, for example, a patient's eye. In general, the drug reservoir 108 can be refilled by inserting a refill needle 120 into and through the needle entry port 116. As described, for example, in U.S. Patent Application Publication No. 2008/0039792 entitled “MEMS Device and Method for Delivery of Therapeutic Agents,” the disclosure of which is hereby incorporated herein by reference in its entirety, the drug-delivery device 100 may be mechanically (e.g., manually) or electrolytically actuated to deliver the therapeutic fluid to a targeted site.
  • FIG. 2 schematically illustrates the internal structure of the drug-delivery device 100 between the needle entry port 116 and the drug reservoir 108 in accordance with one embodiment of the invention. As illustrated, the needle entry port 116 includes a surface 124 and a throat 128 for receiving the refill needle 120 therethrough. The throat 128 opens into a vestibule 132 that is in fluid communication (through, for example, a check valve 136) with the drug reservoir 108. The refill needle 120 pierces, as depicted, the surface 124 of the needle entry port 116, travels through its throat 128, and thereby gains access to the vestibule 132. In one embodiment, injection of a therapeutic fluid from the needle 120 into the vestibule 132 forces the fluid through the check valve 136 and into the reservoir 108, thereby refilling the reservoir 108.
  • As also illustrated in FIGS. 1 and 2, a visualization ring 140 may surround the needle entry port 116 of the implantable drug-delivery device 100. In one embodiment, the visualization ring 140 is made of a material or pigment that is visible through ocular tissue (e.g., through a patient's conjunctiva) so as to visually indicate a position of the needle entry port 116 to a user of the device 100 (e.g., a physician) when the device 100 is implanted within a patient's eye. In addition, the material or pigment forming the visualization ring 140 may be biocompatible and/or able to withstand penetration by the refill needle 120 if and when the refill needle 120 is accidently placed in contact therewith. Exemplary materials from which the visualization ring 140 may be constructed include, but are not limited to, PDMS, polyimide, PEEK, gold, stainless steel, and titanium. The material or pigment forming the visualization ring 140 may optionally fluoresce when exposed to a particular type of light, such as ultraviolet (UV) light. In daylight, fluorescent pigments have a white or light color and are therefore generally cosmetically invisible. Under excitation by UV radiation, however, the fluorescent pigments typically irradiate an intensive fluorescent color. Exemplary pigments that may form the visualization ring 140, or a portion thereof, include, but are not limited to, luminescent aerogels, nanoparticles (e.g., silicon nanoparticles), phthalocyanine (PC) pigments, fluorescein isothiocyanate, rhodamine (TRITC), coumarin, cyanine, Alexa Fluors, DyLight Fluors, quantum dots, green fluorescent proteins, and/or luciferins. By using such pigments, the visualization ring 140 and its substrates may generally be cosmetically invisible until such time as the physician exposes the ring 140 to UV light. At that point, the physician can easily visualize the ring 140, either visually or with the aid of, for example, a fluorescence stereo microscope.
  • The visualization ring 140 may also be made with materials that enhance surface echogenicity and acoustic shadowing so that the physician may better visualize the needle entry port 116 when using certain imaging devices. Such materials include metals, semiconductors, and advanced composite materials that cause the visualization ring 140 to become more reflective or absorbent to ultrasound waves or infrared light (in contrast to the other materials on the non-ring portions of the drug-delivery device 100 that are not desired to be visualized) during such times as when the physician uses an ultrasound scanner, an optical coherence tomography (OCT) visualization tool, or other coherence scanner for visualizing the ring 140 subcutaneously. For example, if the outer shell of the drug-delivery device 100 is made of polyimide (a less reflective material), but the visualization ring 140 is lined with gold (a more reflective material), then the visualization ring 140 will be more easily visualized by the physician when using an OCT scanner or ultrasound scanner since the light, laser, or sound will be reflected differently by the gold.
  • In another embodiment, the visualization ring 140 includes one or more light emitting diodes (LEDs) that illuminate during the desired time of refilling. For example, the drug-delivery device 100 may include an internal power supply (e.g., a battery) and other electronics to supply power to the LEDs. Then, the physician may activate the power supply and electronics wirelessly (e.g., using a device that emits a radio-frequency (RF) signal) to turn the LEDs on just prior to refilling the drug-delivery device 100. Alternatively, where it is desired to hermetically package the electronic devices (including the LEDs) within the drug-delivery device 100, the LEDs may be located in a different part of the drug-delivery device 100 (e.g., distant from the visualization ring 140) and a conduit, such as a bundle of optical fiber, may be used to conduct the light from the LEDs to the visualization ring 140 and also around the visualization ring 140.
  • In yet another embodiment, the visualization ring 140 and/or the needle entry port 116 moves up and down, or vibrates, in a manner that gives the physician a tactile sensation confirming the location of the visualization ring 140 and/or needle entry port 116. Again, such movement and/or vibration may be imparted to the visualization ring 140 and/or the needle entry port 116 through the use of electronics internal to the drug-delivery device 100. Those electronics may be activated remotely through, for example, a handheld device emitting an RF signal.
  • In still another embodiment, the visualization ring 140 includes a magnetic material. For example, the visualization ring 140 may be made, at least in part, from a ferromagnetic material alone, or it may include a ferromagnetic material encased in a ceramic. The refill needle 120 used in combination with such a visualization ring 140 may likewise contain magnetic materials, for example on a tip 208 and/or shaft 212 thereof, and/or on a stop 224 connected thereto (see FIG. 3). In this way, the magnetic materials of the visualization ring 140 may attract the magnetic materials of the refill needle 120, thereby aiding the physician in locating the needle entry port 116. In addition, the magnetic materials of the visualization ring 140 and the refill needle 120 may aid in aligning the shaft 212 of the refill needle 120 with the elongate axes of the throat 128 and vestibule 132, thereby preventing the needle 120 from contacting (and potentially puncturing) a sidewall 144 of the vestibule 132.
  • Since the needle entry port 116 may be very small, and the physician may be injecting drugs in an invasive manner, it is often useful to add a secondary or tertiary confirmatory signal for the location of the visualization ring 140 and the needle entry port 116, such as sight, sound, tactile sensation, and/or magnetic interaction.
  • In one embodiment, as illustrated in FIG. 2, the visualization ring 140 is embedded into (and thus completely surrounded by) the material forming the surface 124 of the needle entry port 116. In this way, the visualization ring 140 does not come into contact with the patient's body or with any medications delivered to the device 100 by the refill needle 120. In certain embodiments, this is important. For example, the use of some materials in the visualization ring 140, such as rhodamine pigments, can be toxic to the patient's body or degrade over time if not properly sealed with the material forming the surface 124.
  • The visualization ring 140 may be an annulus and, as illustrated in FIG. 2, its inner diameter may define the width w1 of the throat 128 through which the refill needle 120 passes when it is inserted into the needle entry port 116. Moreover, in one embodiment, the width w2 of the vestibule 132 is greater than the width w1 of the throat 128. In this way, the smaller width w1 of the throat 128 constrains the movement of the refill needle 120 as it is advanced into the vestibule 132 and aids in preventing the needle 120 from contacting (and potentially puncturing) the sidewall 144 of the vestibule 132.
  • In addition to the visualization ring 140, an insertion guider (not shown) may be positioned at a top surface of, or within, the needle entry port 116 to aid in guiding the refill needle 120 along the elongate axis of the vestibule 132 (and not into the sidewall 144). The insertion guider may be cylindrical in shape, or have another shape. In addition, the insertion guider may be removable and may be placed on top of the needle entry port 116 and mechanically or magnetically locked to the needle entry port 116 just prior to the refilling procedure.
  • As mentioned, a physician may pierce the surface 124 of the needle entry port 116 with the refill needle 120 as he or she advances the needle 120 into the vestibule 132 of the drug-delivery device 100. In one embodiment, the material of the surface 124 is self-sealing. More specifically, the surface 124 may be formed from a soft plastic material that can be punctured with the needle 120 and that reseals itself upon removal of the needle 120. In one embodiment, the self-sealing material is able to withstand multiple punctures by the needle 120, and is biocompatible. Examples of materials that may be employed for the self-sealing material include, but are not limited to, PDMS, parylene C, parylene HT, polycarbonates, polyolefins, polyurethanes, copolymers of acrylonitrile, copolymers of polyvinyl chloride, polyamides, polysulphones, polystyrenes, polyvinyl fluorides, polyvinyl alcohols, polyvinyl esters, polyvinyl butyrate, polyvinyl acetate, polyvinylidene chlorides, polyvinylidene fluorides, polyimides, polyisoprene, polyisobutylene, polybutadiene, polyethylene, polyethers, polytetrafluoroethylene, polychloroethers, polymethylmethacrylate, polybutylmethacrylate, polyvinyl acetate, nylons, cellulose, gelatin, silicone rubbers and porous rubbers. Where the self-sealing material includes a plastic that is capable of leaching or absorbing drugs that come into contact with it (e.g., silicone), parylene may be coated over the plastic so that less drug is exposed to the plastic.
  • FIG. 3 depicts one embodiment of the refill needle 120. As illustrated, the refill needle 120 includes a proximal end 200 (i.e., an end closest to an operator of the refill needle 120) and an opposite, distal end 204. In one embodiment, the distal end 204 of the needle 120 terminates in a tip 208, such as a conically-shaped tip. The tip 208 may, of course, have another shape suitable for piercing the surface 124 of the needle entry port 116. For example, as illustrated in FIG. 2, the distal end 204 of the refill needle 120 may be cut (or otherwise formed) at an oblique angle to form an oblique tip 208.
  • A hollow shaft 212 (i.e., a shaft having a lumen that extends therethrough) extends from the proximal end 200 of the refill needle 120 to a proximal end 216 of the tip 208. In addition, as illustrated, the refill needle 120 may include at least one fluid exit port 220 positioned along the shaft 212 (e.g., near the tip 208). For example, the refill needle 120 may include, near the proximal end 216 of the tip 208, two fluid exit ports 220 positioned approximately 180° apart around the circumference of the shaft 212. Alternatively, the fluid exit port(s) 220 may be positioned elsewhere along the shaft 212. The fluid exit port(s) 220 is/are in fluid communication with the lumen of the hollow shaft 212. In this way, when the refill needle 120 is positioned within the vestibule 132 of the device 100, as further described below, therapeutic fluid may be passed through the hollow shaft 212 of the needle 120, out its fluid exit port(s) 220, and into the vestibule 132. In addition, the fluid exit port(s) 220 are generally oriented transverse to the long axis of the refill needle 120. In this fashion, the refill needle 120 may be inserted into the needle entry port 116 of the device 100 with reduced risk of occluding the exit port(s) 220 with material cored from the walls of the throat 128.
  • With reference still to FIG. 3, the refill needle 120 may also include a means for limiting an extent of entry of the needle 120 into the needle entry port 116. For example, the limitation means may be a stop 224 fixedly mounted to the needle shaft 212. As illustrated, the stop 224 may be mounted to the shaft 212 at a point proximal to the fluid exit port(s) 220, such that the fluid exit port(s) 220 is/are positioned intermediate to the needle tip 208 and the stop 224. As illustrated in FIG. 4, by positioning the stop 224 an appropriate distance away from both the fluid exit port(s) 220 and the distal end 204 of the refill needle 120, the fluid exit port(s) 220 will be correctly positioned within the vestibule 132 of the device 100 when the stop 224 abuts the surface 124 of the needle entry port 116, and the tip 208 at the distal end 204 of the needle 120 will not contact (or pierce) the bottom wall 148 of the vestibule 132. In one embodiment, to achieve this desired effect, the stop 224 is positioned at a distance from the fluid exit port(s) 120 that is greater than the height h1 of the throat 128 of the needle entry port 116, and also at a distance from the distal end 204 of the refill needle 120 that is less than the combined height h2 of the throat 128 and vestibule 132. In this way, the stop 224 decreases the likelihood of the refill needle 220 penetrating the entire drug-delivery device 100 and entering, for example, the patient's eye. The stop 224 also prevents the tip 208 of the refill needle 120 from becoming embedded in the bottom wall 148 of the vestibule 132, where the fluid exit port(s) 220 and lumen of the needle 120 may be occluded, thereby preventing therapeutic fluid from being dispensed into the vestibule 132.
  • In one embodiment, as illustrated in FIG. 3, the stop 224 is a ring that surrounds the shaft 212 of the refill needle 120. So that the stop 224 halts the progress of the refill needle 120 into the vestibule 132 of the device 100 (i.e., limits the depth to which the refill needle 120 can be inserted into the vestibule 132), the ring, in one embodiment, has an outer diameter d1 that exceeds the width w1 of the throat 128. In this way, the stop 224 and the portion of the refill needle 120 proximate to the stop 224 are prevented from entering the needle entry port 116. The outer contour of the stop 224 need not take the form of a ring. For example, the stop 224 may have an outer shape that is generally spherical, cylindrical, rectangular, or pyramidal, or may be shaped in another manner suitable for carrying out the functions of the stop 224 described herein.
  • The stop 224 may be constructed of a metal, a plastic, a composite material, or a combination thereof. The metal, plastic, and/or composite material may be biocompatible, or not. In one embodiment, the stop 224 is constructed of PDMS. Alternatively, the stop 224 may be constructed of other material, or combinations of materials, that have the requisite mechanical strength to perform the function of the stop 224 described herein. For example, the stop 224 may also be constructed of polyimide, polypropylene, PEEK, polycarbonate, acetyl film (e.g., acetyl copolymer), polyoxymethylene plastic (e.g., Delrin®), gold, stainless steel, nickel, and/or chrome. The stop 224 may also take the form of an integral, disk-like protrusion from (and extending around) the needle shaft 212, introduced during the manufacture thereof.
  • In practice, an exemplary refill needle 120 may be prepared by pinching closed a hollow 30-gauge needle and deburring the closure to leave a conical tip 208 of approximately 254 μm in height. Two exit ports 220, each measuring approximately 101 μm in diameter, may then drilled through refill needle 120 approximately 127 μm above the proximal end 216 of the conical tip 208. A stop 224 may then be fabricated by laser-cutting a thin PDMS membrane into an appropriately sized ring shape. As will be understood by one of ordinary skill in the art, the inner diameter of the ring-shaped stop 224 is determined by the size of the outer diameter of the refill needle 120 (i.e., approximately 305 μm for a 30-gauge needle). The PDMS ring-shaped stop 224 may then be fitted onto the shaft 212 of the needle 120 and secured by, for example, a glue. The location on the shaft 212 to which the ring-shaped stop 224 is secured is chosen as described above.
  • In another embodiment, rather than fixedly mounting a stop 224 on the outside of the shaft 212 of the refill needle 120, or in addition thereto, a stop may be positioned within the vestibule 132 of the drug-delivery device 100 itself. For example, as illustrated in FIG. 5, a stop 152 may be secured to, and caused to extend from, the bottom wall 148 of the vestibule 132 (i.e., a wall of the vestibule 132 opposite the throat 128), for example by gluing the stop 152 to the wall 148. In this way, the progress of the refill needle 120 into the vestibule 132 through the throat 128 halts when the tip 208 of the needle 120 contacts the stop 152. Again, in this embodiment, the stop 152 may be sized (i.e., in height), and the fluid exit port(s) 220 placed on the shaft 212 of the refill needle 120, so that the progress of the needle 120 into the vestibule 132 is halted at a point at which the exit port(s) 220 is/are in fluid communication with the vestibule 132.
  • The stop 152 may be a rectangular prism, a cylinder, or any other shape suitable for carrying out the functions of the stop 152 described herein. As illustrated in FIG. 5, a top surface 160 of the stop 152 may be flat. Alternatively, the stop 152 may be shaped as a cup (e.g., the top surface 160 of the stop 152 may be cup-shaped or concave). In this way, the stop 152 may also aid in preventing the refill needle 120 from contacting, and possibly penetrating, the sidewall 144 of the vestibule 132.
  • In addition, like the stop 224 of the refill needle 120, the stop 152 may be constructed of a metal, a hard (e.g., fully cross-linked or reinforced) plastic, a composite material, or a combination thereof. For example, the stop 152 may be constructed from a thick layer of PDMS (i.e., a thicker layer than that used for the puncturable surface 124 of the needle entry port 116), polyimide, polypropylene, PEEK, polycarbonate, acetyl film (e.g., acetyl copolymer), polyoxymethylene plastic (e.g., Delrin®), gold, stainless steel, nickel, and/or chrome. The stop 152 may be biocompatible, or not. In general, the stop 152 may be constructed of any relatively rigid and mechanically robust material, or combinations of materials, that have the requisite mechanical strength for performing the functions of the stop 152 described herein.
  • FIG. 6 schematically illustrates the exemplary drug-delivery device 100 implanted in the eye of a patient in accordance with one embodiment of the invention. As illustrated, the device 100 is placed upon the conjunctiva of the eye, and the cannula 112 is inserted therethrough in to the posterior chamber of the eye. The drug-delivery device 100 administers therapeutic fluid to the posterior chamber of the eye through the cannula 112 and a check valve 156, which may control the delivery of the fluid and prevent backflow. In other embodiments, the device 100 is used to administer fluid to the anterior chamber of the eye, which is separated from the posterior chamber by the lens.
  • An operator of the drug-delivery device 100 (e.g., a physician) may refill the device 100 in situ (i.e., without having to remove the device 100 from the patient's eye). To do so, in one embodiment, the operator first locates the visualization ring 140 of the device 100. The operator may locate the visualization ring 140 by simple visual inspection because, as described above, the visualization ring 140 is constructed of a material that is visible through the patient's conjunctiva. Moreover, because the visualization ring 140 surrounds the needle entry port 116, it visually indicates the position of that needle entry port 116 to the operator.
  • Once the visualization ring 140 and needle entry port 116 are located, the operator inserts the distal tip 208 of the refill needle 120 into the needle entry port 116 of the drug-delivery device 100. More specifically, the operator may contact the surface 124 of the needle entry port 116 with the distal tip 208 of the refill needle 120, pierce the surface 124 by advancing the needle 120, and further advance the needle 120 into the throat 128 and then the vestibule 132 of the drug-delivery device 100. In an embodiment where the refill needle 120 includes the stop 224 fixedly mounted to (or integral with) its shaft 212, the operator may continue to advance the needle 120 into the needle entry port 116 until the stop 224 contacts the surface 124 of the needle entry port 116, thereby limiting further entry of the needle 120 into the needle entry port 116. Alternatively, in an embodiment where the vestibule 132 includes the stop 152 fixedly mounted to its bottom wall 148, the operator may continue to advance the refill needle 120 into the needle entry port 116 until the distal tip 208 of the needle 120 contacts the stop 152, which then halts further entry of the needle 120 into the vestibule 132.
  • At the point of the stop 224 and/or the stop 152 acting to limit further entry of the needle 120 into the vestibule 132, the operator will be assured, as described above, that the exit port(s) 220 of the refill needle 120 is/are properly placed within the vestibule 132 and in fluid communication therewith. The operator may then cause a therapeutic fluid (e.g., a drug in liquid form) to be delivered through the hollow shaft 212 of the refill needle 120, out the fluid exit port(s) 220, and into the vestibule 132 of the drug-delivery device 100. Injection of the therapeutic fluid from the needle 120 into the vestibule 132 forces the fluid through the check valve 136 and into the reservoir 108, thereby refilling the reservoir 108.
  • Accordingly, as described herein, the operator may rapidly refill the drug-delivery device 100 in situ, while the risk of damage to the device 100 and injury to the patient are also minimized.
  • Having described certain embodiments of the invention, it will be apparent to those of ordinary skill in the art that other embodiments incorporating the concepts disclosed herein may be used without departing from the spirit and scope of the invention. For example, the drug-delivery device 100 may also be implanted in other portions of a patient's body, such as in the sub-arachnoid space of the brain to provide chemotherapy or to provide another type of treatment for the brain, near a tumor in any portion of the patient's body to provide chemotherapy, or in a pancreas that does not respond well to glucose to provide agents (e.g., proteins, viral vectors, etc.) that will trigger insulin release. Accordingly, the described embodiments are to be considered in all respects as only illustrative and not restrictive.

Claims (36)

1. A needle for refilling an implantable drug-delivery device having a needle entry port that comprises a throat for receiving the needle therethrough, the needle comprising:
a hollow shaft terminating in a tip;
a fluid exit port along the shaft proximate to the tip; and
means for limiting an extent of entry of the needle into the entry port.
2. The needle of claim 1, wherein the limitation means comprises a stop on the shaft.
3. The needle of claim 2, wherein the stop is a ring surrounding and fixedly mounted to the shaft, the ring having an outer diameter exceeding a width of the throat.
4. The needle of claim 2, wherein the stop is spherically-shaped, cylindrically-shaped, rectangularly-shaped, or pyramidally-shaped.
5. The needle of claim 1, wherein the limitation means is constructed of a biocompatible material.
6. The needle of claim 1, wherein the limitation means is constructed of at least one of a metal, a plastic, or a composite material.
7. The needle of claim 1, wherein the limitation means is constructed of a material selected from the group consisting of PDMS, polyimide, polypropylene, PEEK, polycarbonate, an acetyl film, polyoxymethylene plastic, gold, stainless steel, nickel, and chrome.
8. The needle of claim 1, wherein the tip is conically-shaped.
9. The needle of claim 1, wherein the fluid exit port is positioned intermediate to the tip and the limitation means.
10. An implantable drug-delivery device, comprising:
a drug reservoir;
a needle entry port comprising a throat for receiving a refill needle therethrough; and
a vestibule into which the throat opens, the vestibule (i) being wider than the throat, (ii) comprising a stop on a wall opposite the throat for halting progress of a needle into the vestibule through the throat, and (iii) being in fluid communication with the drug reservoir.
11. The implantable drug-delivery device of claim 10, wherein the stop is sized so as to halt the progress of a needle comprising an exit port at a point at which the exit port is in fluid communication with the vestibule.
12. The implantable drug-delivery device of claim 10, wherein a top surface of the stop is cup-shaped.
13. The implantable drug-delivery device of claim 10, wherein the stop is constructed of a biocompatible material.
14. The implantable drug-delivery device of claim 10, wherein the stop is constructed of at least one of a metal, a plastic, or a composite material.
15. The implantable drug-delivery device of claim 10, wherein the stop is constructed of a material selected from the group consisting of PDMS, polyimide, polypropylene, PEEK, polycarbonate, an acetyl film, polyoxymethylene plastic, gold, stainless steel, nickel, and chrome.
16. The implantable drug-delivery device of claim 10 further comprising a check valve located between the vestibule and the drug reservoir.
17. The implantable drug-delivery device of claim 10, wherein the needle entry port further comprises a self-sealing material.
18. An implantable drug-delivery device, comprising:
a drug reservoir;
a needle entry port comprising a throat for receiving a refill needle therethrough, the throat opening into a vestibule that is in fluid communication with the drug reservoir; and
a visualization ring surrounding the needle entry port, the visualization ring being visible through ocular tissue so as to visually indicate a position of the needle entry port.
19. The implantable drug-delivery device of claim 18, wherein the visualization ring is constructed of a biocompatible material.
20. The implantable drug-delivery device of claim 18, wherein the visualization ring is constructed of a material that withstands penetration by the refill needle.
21. The implantable drug-delivery device of claim 18, wherein the visualization ring is visible through a patient's conjunctiva.
22. The implantable drug-delivery device of claim 18, wherein the visualization ring comprises a fluorescent pigment.
23. The implantable drug-delivery device of claim 22, wherein the fluorescent pigment is selected from the group consisting of a luminescent aerogel, a nanoparticle, a phthalocyanine pigment, fluorescein isothiocyanate, rhodamine, coumarin, cyanine, an Alexa Fluor, a DyLight Fluor, a quantum dot, a green fluorescent protein, and a luciferin.
24. The implantable drug-delivery device of claim 18, wherein the visualization ring comprises a light emitting diode.
25. The implantable drug-delivery device of claim 18 further comprising a light emitting diode and optical fiber for conducting light from the light emitting diode to and around the visualization ring.
26. The implantable drug-delivery device of claim 18, wherein the visualization ring comprises a material that enhances surface echogenicity and acoustic shadowing.
27. The implantable drug-delivery device of claim 18 further comprising electronics to move or vibrate the visualization ring.
28. The implantable drug-delivery device of claim 18, wherein the visualization ring comprises a magnetic material.
29. A method for refilling a drug-delivery device implanted within a patient, comprising:
inserting, into a needle entry port of the drug-delivery device, a distal tip of a needle that comprises a hollow shaft and a stop on the shaft;
advancing the needle into the needle entry port until the stop limits further entry of the needle into the entry port; and
delivering drug through the hollow shaft of the needle, out a fluid exit port positioned along the shaft of the needle proximate the tip, and into the drug-delivery device.
30. The method of claim 29, wherein the stop is a ring surrounding the shaft of the needle, the ring having an outer diameter exceeding a width of the entry port.
31. The method of claim 29 further comprising locating, prior to inserting the distal tip of the needle into the needle entry port, a visualization ring visually indicating the position of the needle entry port.
32. The method of claim 31, wherein the visualization ring surrounds the needle entry port and is visible through the patient's conjunctiva.
33. A method for refilling a drug-delivery device implanted within a patient, comprising:
inserting, into a needle entry port of the drug-delivery device, a distal tip of a needle;
advancing the needle through the needle entry port into a vestibule of the drug-delivery device until a stop positioned on a wall of the vestibule opposite the needle entry port halts further entry of the needle; and
delivering drug through a hollow shaft of the needle, out a fluid exit port positioned along the shaft of the needle proximate the tip, and into the vestibule.
34. The method of claim 33, wherein the stop halts further entry of the needle at a point at which the exit port of the needle is in fluid communication with the vestibule.
35. The method of claim 33 further comprising locating, prior to inserting the distal tip of the needle into the needle entry port, a visualization ring visually indicating the position of the needle entry port.
36. The method of claim 35, wherein the visualization ring surrounds the needle entry port and is visible through the patient's conjunctiva.
US12/348,178 2008-01-03 2009-01-02 Implantable drug-delivery devices, and apparatus and methods for refilling the devices Abandoned US20090192493A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/348,178 US20090192493A1 (en) 2008-01-03 2009-01-02 Implantable drug-delivery devices, and apparatus and methods for refilling the devices
US13/868,649 US9901687B2 (en) 2008-01-03 2013-04-23 Implantable drug-delivery devices, and apparatus and methods for refilling the devices

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1874708P 2008-01-03 2008-01-03
US12/348,178 US20090192493A1 (en) 2008-01-03 2009-01-02 Implantable drug-delivery devices, and apparatus and methods for refilling the devices

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/868,649 Division US9901687B2 (en) 2008-01-03 2013-04-23 Implantable drug-delivery devices, and apparatus and methods for refilling the devices

Publications (1)

Publication Number Publication Date
US20090192493A1 true US20090192493A1 (en) 2009-07-30

Family

ID=40513411

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/348,178 Abandoned US20090192493A1 (en) 2008-01-03 2009-01-02 Implantable drug-delivery devices, and apparatus and methods for refilling the devices
US13/868,649 Expired - Fee Related US9901687B2 (en) 2008-01-03 2013-04-23 Implantable drug-delivery devices, and apparatus and methods for refilling the devices

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/868,649 Expired - Fee Related US9901687B2 (en) 2008-01-03 2013-04-23 Implantable drug-delivery devices, and apparatus and methods for refilling the devices

Country Status (8)

Country Link
US (2) US20090192493A1 (en)
EP (3) EP2727616B1 (en)
JP (2) JP2011509120A (en)
DK (1) DK2240220T3 (en)
ES (2) ES2577502T3 (en)
MX (1) MX2010007382A (en)
PL (1) PL2240220T3 (en)
WO (1) WO2009089094A2 (en)

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305550A1 (en) * 2006-03-14 2010-12-02 Ellis Meng Mems device and method for delivery of therapeutic agents
US20110202032A1 (en) * 2008-05-08 2011-08-18 Jason Shih Drug-delivery pumps with dynamic, adaptive control
US20110303016A1 (en) * 2009-02-24 2011-12-15 University Of Southern California Flexible polymer-based encapsulated-fluid devices
WO2012027435A2 (en) * 2010-08-24 2012-03-01 Qwtip Llc System and method for separating fluids and creating magnetic fields
US8277830B2 (en) 2009-01-29 2012-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US20130023813A1 (en) * 2011-07-19 2013-01-24 Abbott Cardiovascular Systems, Inc. Drug Delivery Device and Method
US8430804B2 (en) 2008-01-07 2013-04-30 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye
WO2013040247A3 (en) * 2011-09-16 2013-05-10 Forsight Vision4, Inc. Fluid exchange apparatus and methods
USD691268S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to eye
USD691269S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to an eye
USD691267S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to eye
USD691270S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to an eye
US20130289482A1 (en) * 2008-01-03 2013-10-31 Ellis Fan-chuin Meng Implantable drug-delivery devices, and apparatus and methods for refilling the devices
US8602959B1 (en) 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
US8608632B1 (en) 2009-07-03 2013-12-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US20150038941A1 (en) * 2008-08-13 2015-02-05 Smed-Ta/Td, Llc Drug delivery implants
US9056201B1 (en) 2008-01-07 2015-06-16 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US9107995B2 (en) 2008-05-08 2015-08-18 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9222819B2 (en) 2009-02-20 2015-12-29 University Of Southern California Tracking and controlling fluid delivery from chamber
US9271866B2 (en) 2007-12-20 2016-03-01 University Of Southern California Apparatus and methods for delivering therapeutic agents
US9333297B2 (en) 2008-05-08 2016-05-10 Minipumps, Llc Drug-delivery pump with intelligent control
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US20170071785A1 (en) * 2015-09-11 2017-03-16 California Institute Of Technology Implantable oxygen generator and transporter
US9603997B2 (en) 2011-03-14 2017-03-28 Minipumps, Llc Implantable drug pumps and refill devices therefor
US20170100598A1 (en) * 2015-10-13 2017-04-13 Glusense Ltd. Implant illumination
US9623174B2 (en) 2008-05-08 2017-04-18 Minipumps, Llc Implantable pumps and cannulas therefor
USD808529S1 (en) 2016-08-31 2018-01-23 Salutaris Medical Devices, Inc. Holder for a brachytherapy device
USD808528S1 (en) 2016-08-31 2018-01-23 Salutaris Medical Devices, Inc. Holder for a brachytherapy device
US9873001B2 (en) 2008-01-07 2018-01-23 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US9919099B2 (en) 2011-03-14 2018-03-20 Minipumps, Llc Implantable drug pumps and refill devices therefor
USD814637S1 (en) 2016-05-11 2018-04-03 Salutaris Medical Devices, Inc. Brachytherapy device
USD814638S1 (en) 2016-05-11 2018-04-03 Salutaris Medical Devices, Inc. Brachytherapy device
USD815285S1 (en) 2016-05-11 2018-04-10 Salutaris Medical Devices, Inc. Brachytherapy device
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9987417B2 (en) 2008-05-08 2018-06-05 Minipumps, Llc Implantable drug-delivery devices, and apparatus and methods for filling the devices
US10022558B1 (en) 2008-01-07 2018-07-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US10286146B2 (en) 2011-03-14 2019-05-14 Minipumps, Llc Implantable drug pumps and refill devices therefor
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10492945B2 (en) 2017-05-22 2019-12-03 California Institute Of Technology Small molecule transport device with anti-condensation filler for drug delivery or waste removal
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10575765B2 (en) 2014-10-13 2020-03-03 Glusense Ltd. Analyte-sensing device
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
CN111655206A (en) * 2017-11-21 2020-09-11 弗赛特影像4股份有限公司 Fluid exchange device for expandable port delivery system and method of use
US10850045B2 (en) 2014-04-03 2020-12-01 Toppan Printing Co., Ltd. Puncture injection instrument
US10871487B2 (en) 2016-04-20 2020-12-22 Glusense Ltd. FRET-based glucose-detection molecules
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10946182B2 (en) 2017-03-07 2021-03-16 Medi Tulip Co., Ltd. Subcutaneous vein access port and medicine injection device having the same
US11351057B2 (en) * 2018-09-17 2022-06-07 Alcon Inc. Low friction trocar valve
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6335904B2 (en) * 2012-10-05 2018-05-30 ユニバーシティ オブ サザン カリフォルニア Oxygen supply
JP6314585B2 (en) * 2014-03-26 2018-04-25 宇部興産株式会社 Tenter device
US20180200185A1 (en) 2015-07-23 2018-07-19 Novaflux, Inc Implants and constructs including hollow fibers

Citations (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4543088A (en) * 1983-11-07 1985-09-24 American Hospital Supply Corporation Self-sealing subcutaneous injection site
US4553973A (en) * 1982-07-12 1985-11-19 Alza Corporation Process for preparing osmotic device
US4738657A (en) * 1985-09-30 1988-04-19 Mcghan Medical Corporation Self-sealing injection reservoir
US4751926A (en) * 1986-09-12 1988-06-21 Dow Corning Wright Corporation Instrument for subcutaneous insertion of an injection reservoir
US4760837A (en) * 1987-02-19 1988-08-02 Inamed Development Company Apparatus for verifying the position of needle tip within the injection reservoir of an implantable medical device
US4781675A (en) * 1985-11-27 1988-11-01 White Thomas C Infusion cannula
US4781695A (en) * 1986-07-11 1988-11-01 Dalton Michael J Implantable fluid dispenser
US4838887A (en) * 1987-12-15 1989-06-13 Shiley Infusaid Inc. Programmable valve pump
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4888176A (en) * 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5135499A (en) * 1989-07-12 1992-08-04 Apcis Device for delivering a pharmacologically active principle by electrolytic pumping
US5147647A (en) * 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5171213A (en) * 1991-08-14 1992-12-15 Price Jr Francis W Technique for fistulization of the eye and an eye filtration prosthesis useful therefor
US5178604A (en) * 1990-05-31 1993-01-12 Iovision, Inc. Glaucoma implant
US5252192A (en) * 1992-10-19 1993-10-12 Hughes Aircraft Company Electrolytic pump
US5312357A (en) * 1991-11-04 1994-05-17 Drager Medical Electonic B.V. Catheter
US5389077A (en) * 1993-03-03 1995-02-14 Uresil Corporation Minimally invasive body cavity penetrating instruments
US5407441A (en) * 1992-06-04 1995-04-18 Greenbaum; Scott Ophthalmologic cannula
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5462739A (en) * 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
US5472436A (en) * 1994-07-26 1995-12-05 Fremstad; Daria A. Ocular appliance for delivering medication
US5476445A (en) * 1990-05-31 1995-12-19 Iovision, Inc. Glaucoma implant with a temporary flow restricting seal
US5478328A (en) * 1992-05-22 1995-12-26 Silverman; David G. Methods of minimizing disease transmission by used hypodermic needles, and hypodermic needles adapted for carrying out the method
US5704520A (en) * 1993-07-19 1998-01-06 Elan Medical Technologies, Limited Liquid material dispenser and valve
US5725017A (en) * 1997-01-27 1998-03-10 Medtronic, Inc. In-line pressure check valve for drug-delivery systems
US5725493A (en) * 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5798115A (en) * 1996-02-15 1998-08-25 Santerre; Paul J. Bioresponsive pharmacologically-active polymers and articles made therefrom
US5836935A (en) * 1994-11-10 1998-11-17 Ashton; Paul Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5868697A (en) * 1995-05-14 1999-02-09 Optonol Ltd. Intraocular implant
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US5989579A (en) * 1986-10-02 1999-11-23 Escalon Medical Corp. Ocular insert with anchoring protrusions
US6144106A (en) * 1996-10-04 2000-11-07 Dow Corning Corporation Electronic coatings
US6264971B1 (en) * 1999-11-04 2001-07-24 Btg International Limited Ocular insert
US6281192B1 (en) * 1999-03-01 2001-08-28 Vista Scientific Llc Mucin containing ophthalmic preparations
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US20020103412A1 (en) * 2001-02-01 2002-08-01 William Trimmer Micro pump
US20020188282A1 (en) * 2001-02-13 2002-12-12 Robert Greenberg Implantable drug delivery device
US20030014036A1 (en) * 2001-06-12 2003-01-16 Varner Signe Erickson Reservoir device for intraocular drug delivery
US6520936B1 (en) * 1999-06-08 2003-02-18 Medtronic Minimed, Inc. Method and apparatus for infusing liquids using a chemical reaction in an implanted infusion device
US6527744B1 (en) * 1997-08-27 2003-03-04 Science Incorporated Fluid delivery device with light activated energy source
US6537268B1 (en) * 1998-06-18 2003-03-25 Medtronic Minimed, Inc. Medical infusion device with a source of controlled compliance
US20030064088A1 (en) * 2001-08-29 2003-04-03 Carvalho Ricardo Azevedo Pontes De Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
US20030069560A1 (en) * 2001-05-03 2003-04-10 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US20030141618A1 (en) * 2001-11-30 2003-07-31 Cambridge Polymer Group, Inc. Layered aligned polymer structures and methods of making same
US20040028655A1 (en) * 1999-08-06 2004-02-12 Nelson Kevin D. Drug releasing biodegradable fiber for delivery of therapeutics
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6719750B2 (en) * 2000-08-30 2004-04-13 The Johns Hopkins University Devices for intraocular drug delivery
US20040143221A1 (en) * 2002-12-27 2004-07-22 Shadduck John H. Biomedical implant for sustained agent release
US20040199130A1 (en) * 2003-04-03 2004-10-07 Chornenky Victor I. Apparatus and method for treatment of macular degeneration
US6852106B2 (en) * 2000-12-14 2005-02-08 Control Delivery Systems, Inc. Implantable refillable and ported controlled release drug delivery device
US20050175708A1 (en) * 2002-05-02 2005-08-11 Carrasquillo Karen G. Drug delivery systems and use thereof
US20050187515A1 (en) * 2004-02-19 2005-08-25 Advanced Neuromodulation Systems, Inc. Reduced size programmable drug pump
US20050208103A1 (en) * 1999-01-05 2005-09-22 Adamis Anthony P Targeted transscleral controlled release drug delivery to the retina and choroid
US7070577B1 (en) * 1998-02-02 2006-07-04 Medtronic, Inc Drive circuit having improved energy efficiency for implantable beneficial agent infusion or delivery device
US20060167435A1 (en) * 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
US20060258994A1 (en) * 2005-05-12 2006-11-16 Avery Robert L Implantable delivery device for administering pharmacological agents to an internal portion of a body
US20060259015A1 (en) * 2005-05-10 2006-11-16 Palion Medical Corporation Implantable pump with infinitely variable resistor
US20070021735A1 (en) * 2005-07-15 2007-01-25 Sai Bhavaraju Dual membrane electro-osmotic fluid delivery device
US20070112328A1 (en) * 2005-05-10 2007-05-17 Palyon Medical Corporation Variable flow infusion pump system
US7276050B2 (en) * 2004-03-02 2007-10-02 Alan Franklin Trans-scleral drug delivery method and apparatus
US20070255235A1 (en) * 2006-04-28 2007-11-01 Olsen James M Septum monitoring system and method for an implantable therapeutic substance delivery device
US20070255261A1 (en) * 2006-04-27 2007-11-01 Haase James M Infusion device with active and passive check valves
US20080039792A1 (en) * 2006-03-14 2008-02-14 Ellis Meng Mems device and method for delivery of therapeutic agents

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3731681A (en) 1970-05-18 1973-05-08 Univ Minnesota Implantable indusion pump
FR2091189A5 (en) 1970-05-18 1972-01-14 Regents University Minne
BE792363A (en) * 1971-12-06 1973-06-06 Mpl Inc LIQUID DISPENSER AND METHOD AND APPARATUS FOR FILLING IT
US4150673A (en) 1977-02-03 1979-04-24 Pharmachem Corporation Coded entry system for blood bag
US4525165A (en) 1979-04-27 1985-06-25 The Johns Hopkins University Fluid handling system for medication infusion system
US4573994A (en) 1979-04-27 1986-03-04 The Johns Hopkins University Refillable medication infusion apparatus
FR2582222A1 (en) * 1985-05-21 1986-11-28 Applied Precision Ltd IMPLANTABLE MANUAL ACTION DEVICE FOR THE SEQUENTIAL DELIVERY OF DOSES OF A SUBSTANCE, ESPECIALLY THERAPEUTIC
US4673394A (en) * 1986-01-17 1987-06-16 Strato Medical Corporation Implantable treatment reservoir
CA1311686C (en) 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
US4804054A (en) * 1987-06-01 1989-02-14 Intelligent Medicine, Inc. Device and method for precise subcutaneous placement of a medical instrument
US4955861A (en) 1988-04-21 1990-09-11 Therex Corp. Dual access infusion and monitoring system
DD274863A1 (en) 1988-08-12 1990-01-03 Komb Medizin Und Labor Technik SAFETY VALVE FOR MINIMAL FLOW RATE, ESPECIALLY FOR IMPLANTABLE INFUSION PUMPS
JPH02191468A (en) 1988-10-03 1990-07-27 Olympus Optical Co Ltd Subcataneous terminal
US5007647A (en) 1989-12-15 1991-04-16 Sports Glow, Inc. Golf ball and method of making same
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US6564087B1 (en) 1991-04-29 2003-05-13 Massachusetts Institute Of Technology Fiber optic needle probes for optical coherence tomography imaging
US5201715A (en) 1991-11-19 1993-04-13 Mcghan Medical Corporation Implantable devices having ultrasonic echographic signature
DE4333736A1 (en) * 1993-10-04 1995-04-06 Anschuetz & Co Gmbh Infusion pump
DE4436540C2 (en) * 1994-10-13 1997-03-06 Fresenius Ag Locking device for a device for supplying a liquid medicament under pressure
JP3503852B2 (en) 1995-11-15 2004-03-08 本田技研工業株式会社 Mounting structure of steering gear box
US5702432A (en) * 1996-10-03 1997-12-30 Light Sciences Limited Partnership Intracorporeal light treatment of blood
AU8491098A (en) * 1997-07-18 1999-02-10 Vasca, Inc. Method and apparatus for percutaneously accessing an implanted port
WO1999017749A1 (en) 1997-10-02 1999-04-15 Iep Group, Inc. A micromachined valve for fluid applications
US6589198B1 (en) 1998-01-29 2003-07-08 David Soltanpour Implantable micro-pump assembly
US6203523B1 (en) 1998-02-02 2001-03-20 Medtronic Inc Implantable drug infusion device having a flow regulator
US6159160A (en) 1998-03-26 2000-12-12 Ethicon, Inc. System and method for controlled infusion and pressure monitoring
EP1082151A1 (en) 1998-06-04 2001-03-14 ELAN CORPORATION, Plc Gas driven drug delivery device
WO2000026367A2 (en) 1998-10-29 2000-05-11 The University Of Iowa Research Foundation Therapeutics and diagnostics for ocular abnormalities
US8177762B2 (en) 1998-12-07 2012-05-15 C. R. Bard, Inc. Septum including at least one identifiable feature, access ports including same, and related methods
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6471689B1 (en) 1999-08-16 2002-10-29 Thomas Jefferson University Implantable drug delivery catheter system with capillary interface
US6413238B1 (en) 1999-09-17 2002-07-02 Baxter International Inc Fluid dispenser with stabilized fluid flow
US6519569B1 (en) 1999-12-01 2003-02-11 B. Braun Medical, Inc. Security infusion pump with bar code reader
WO2001056634A1 (en) 2000-02-03 2001-08-09 Medtronic, Inc. Variable infusion rate catheter
US6478783B1 (en) 2000-05-26 2002-11-12 H. Robert Moorehead Anti-sludge medication ports and related methods
US20020040208A1 (en) 2000-10-04 2002-04-04 Flaherty J. Christopher Data collection assembly for patient infusion system
JPWO2002040208A1 (en) 2000-11-20 2004-03-18 三菱電機株式会社 Wire electric discharge machining method and apparatus
JP4996015B2 (en) 2001-03-12 2012-08-08 メディキット株式会社 Indwelling catheter
AU2002320423A1 (en) 2001-06-27 2003-03-03 Durect Corporation Minimally invasive drug delivery catheter
WO2003009774A2 (en) 2001-07-23 2003-02-06 Alcon, Inc. Ophthalmic drug delivery device
JP4249611B2 (en) * 2001-07-23 2009-04-02 アルコン,インコーポレイティド Ophthalmic drug delivery device
PL366787A1 (en) 2001-08-27 2005-02-07 Novo Nordisk A/S A cartridge and a medical delivery system accommodating such a cartridge
US6976974B2 (en) 2002-10-23 2005-12-20 Scimed Life Systems, Inc. Rotary manifold syringe
EP1741457A1 (en) 2002-08-09 2007-01-10 Ottawa Health Research Institute Ocular implant
US6962580B2 (en) 2002-09-17 2005-11-08 Transoma Medical, Inc. Vascular access port with needle detector
US20040064030A1 (en) 2002-10-01 2004-04-01 Peter Forsell Detection of implanted injection port
WO2004066871A2 (en) 2003-01-24 2004-08-12 Doheny Retina Institute Reservoirs with subretinal cannula for subretinal drug delivery
US7191011B2 (en) * 2003-04-07 2007-03-13 Advanced Neuromodulation Systems, Inc. Access port indicator for implantable medical device
US7174923B2 (en) 2003-10-31 2007-02-13 Codman & Shurtleff, Inc. Refill kit for an implantable pump
WO2005046769A2 (en) * 2003-11-12 2005-05-26 Vidacare Corporation Reusable intraosseous device and method for accessing bone marrow in the sternum
WO2005084274A2 (en) * 2004-03-02 2005-09-15 Medical Research Products-A, Inc. Medical device needle receiving port
GB0508531D0 (en) 2005-04-27 2005-06-01 Smith & Nephew Sai with ultrasound
DE202004008151U1 (en) * 2004-05-24 2005-10-06 Möller Medical GmbH & Co. KG Medical needle for inserting into a catheter system comprises a cannula having a protrusion on the distal end
US20060079839A1 (en) * 2004-06-29 2006-04-13 Becton, Dickinson And Company Single-use syringe
WO2006014793A1 (en) 2004-07-26 2006-02-09 Clarity Corporation Implantable device having reservoir with controlled release of medication and method of manufacturing the same
US7637897B2 (en) 2004-10-25 2009-12-29 Codman Neuro Sciences Sarl Implantable pump with integrated refill detection
WO2006075016A1 (en) 2005-01-17 2006-07-20 Novo Nordisk A/S Fluide delivery device with integrated monitoring of physiological characteristics
WO2006079055A2 (en) * 2005-01-24 2006-07-27 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
WO2006096686A1 (en) 2005-03-04 2006-09-14 C.R. Bard, Inc. Access port identification systems and methods
US20060235428A1 (en) * 2005-04-14 2006-10-19 Silvestrini Thomas A Ocular inlay with locator
EP1896117B1 (en) 2005-04-27 2011-01-12 C.R.Bard, Inc. Power injector system for injecting contrast media into an intravenous line
US20090227855A1 (en) 2005-08-16 2009-09-10 Medtronic Minimed, Inc. Controller device for an infusion pump
WO2007041471A2 (en) 2005-09-30 2007-04-12 Angiodynamics, Inc. Implantable medical device
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US8163237B2 (en) * 2006-05-08 2012-04-24 Becton, Dickinson And Company Vascular access device pathogenic status indication
US20080045930A1 (en) 2006-08-21 2008-02-21 Ronald Makin System and Method of Drug Identification Through Radio Frequency Identification (RFID)
UY30883A1 (en) 2007-01-31 2008-05-31 Alcon Res PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS
US8251960B2 (en) 2007-03-24 2012-08-28 The Alfred E. Mann Foundation For Scientific Research Valves, valved fluid transfer devices and ambulatory infusion devices including the same
US7828771B2 (en) 2007-07-26 2010-11-09 Entra Pharmaceuticals, Inc. Systems and methods for delivering drugs
US20090088732A1 (en) 2007-10-02 2009-04-02 Daniel Hernandez Villegas Rapid Refill Programming for Implantable Drug Pump
AU2008308451A1 (en) 2007-10-05 2009-04-09 Angiodynamics, Inc. Dual reservoir implantable access port
DK2240220T3 (en) 2008-01-03 2016-08-01 Univ Southern California Implantable devices for drug AND APPARATUS FOR refilling DEVICES
RU2485393C2 (en) 2008-01-17 2013-06-20 Конинклейке Филипс Электроникс Н.В. Lighting device
US8369942B2 (en) * 2008-03-20 2013-02-05 The Invention Science Fund I, Llc Subdermal material delivery device
JP2011519695A (en) 2008-05-08 2011-07-14 リプレニッシュ パンプス, エルエルシー Implantable drug delivery device and apparatus and method for filling the device
CN102202708B (en) 2008-05-08 2015-01-21 迷你泵有限责任公司 Drug-delivery pumps and methods of manufacture
WO2010051494A1 (en) 2008-10-31 2010-05-06 C.R. Bard, Inc. Systems and methods for identifying an acess port
MX2012002063A (en) 2009-08-18 2012-08-01 Minipumps Llc Electrolytic drug-delivery pump with adaptive control.
US9919099B2 (en) 2011-03-14 2018-03-20 Minipumps, Llc Implantable drug pumps and refill devices therefor
US10286146B2 (en) 2011-03-14 2019-05-14 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9603997B2 (en) 2011-03-14 2017-03-28 Minipumps, Llc Implantable drug pumps and refill devices therefor
WO2012125695A1 (en) 2011-03-14 2012-09-20 Minipumps, Llc Instrument and methods for filling an implanted drug pump
WO2013052414A2 (en) 2011-09-30 2013-04-11 Minipumps, Llc Implantable drug pumps and refill devices therefor

Patent Citations (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4553973A (en) * 1982-07-12 1985-11-19 Alza Corporation Process for preparing osmotic device
US4543088A (en) * 1983-11-07 1985-09-24 American Hospital Supply Corporation Self-sealing subcutaneous injection site
US4888176A (en) * 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US4738657A (en) * 1985-09-30 1988-04-19 Mcghan Medical Corporation Self-sealing injection reservoir
US4781675A (en) * 1985-11-27 1988-11-01 White Thomas C Infusion cannula
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4781695A (en) * 1986-07-11 1988-11-01 Dalton Michael J Implantable fluid dispenser
US4751926A (en) * 1986-09-12 1988-06-21 Dow Corning Wright Corporation Instrument for subcutaneous insertion of an injection reservoir
US5989579A (en) * 1986-10-02 1999-11-23 Escalon Medical Corp. Ocular insert with anchoring protrusions
US5147647A (en) * 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4760837A (en) * 1987-02-19 1988-08-02 Inamed Development Company Apparatus for verifying the position of needle tip within the injection reservoir of an implantable medical device
US4838887A (en) * 1987-12-15 1989-06-13 Shiley Infusaid Inc. Programmable valve pump
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5135499A (en) * 1989-07-12 1992-08-04 Apcis Device for delivering a pharmacologically active principle by electrolytic pumping
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5178604A (en) * 1990-05-31 1993-01-12 Iovision, Inc. Glaucoma implant
US5476445A (en) * 1990-05-31 1995-12-19 Iovision, Inc. Glaucoma implant with a temporary flow restricting seal
US5171213A (en) * 1991-08-14 1992-12-15 Price Jr Francis W Technique for fistulization of the eye and an eye filtration prosthesis useful therefor
US5312357A (en) * 1991-11-04 1994-05-17 Drager Medical Electonic B.V. Catheter
US5462739A (en) * 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
US5478328A (en) * 1992-05-22 1995-12-26 Silverman; David G. Methods of minimizing disease transmission by used hypodermic needles, and hypodermic needles adapted for carrying out the method
US5407441A (en) * 1992-06-04 1995-04-18 Greenbaum; Scott Ophthalmologic cannula
US5252192A (en) * 1992-10-19 1993-10-12 Hughes Aircraft Company Electrolytic pump
US5389077A (en) * 1993-03-03 1995-02-14 Uresil Corporation Minimally invasive body cavity penetrating instruments
US5704520A (en) * 1993-07-19 1998-01-06 Elan Medical Technologies, Limited Liquid material dispenser and valve
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5824072A (en) * 1993-11-15 1998-10-20 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5472436A (en) * 1994-07-26 1995-12-05 Fremstad; Daria A. Ocular appliance for delivering medication
US5836935A (en) * 1994-11-10 1998-11-17 Ashton; Paul Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US6251090B1 (en) * 1994-12-12 2001-06-26 Robert Logan Avery Intravitreal medicine delivery
US5725493A (en) * 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5830173A (en) * 1994-12-12 1998-11-03 Avery; Robert Logan Intravitreal medicine delivery
US5868697A (en) * 1995-05-14 1999-02-09 Optonol Ltd. Intraocular implant
US5798115A (en) * 1996-02-15 1998-08-25 Santerre; Paul J. Bioresponsive pharmacologically-active polymers and articles made therefrom
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6144106A (en) * 1996-10-04 2000-11-07 Dow Corning Corporation Electronic coatings
US5725017A (en) * 1997-01-27 1998-03-10 Medtronic, Inc. In-line pressure check valve for drug-delivery systems
US6527744B1 (en) * 1997-08-27 2003-03-04 Science Incorporated Fluid delivery device with light activated energy source
US7070577B1 (en) * 1998-02-02 2006-07-04 Medtronic, Inc Drive circuit having improved energy efficiency for implantable beneficial agent infusion or delivery device
US6537268B1 (en) * 1998-06-18 2003-03-25 Medtronic Minimed, Inc. Medical infusion device with a source of controlled compliance
US20050208103A1 (en) * 1999-01-05 2005-09-22 Adamis Anthony P Targeted transscleral controlled release drug delivery to the retina and choroid
US6281192B1 (en) * 1999-03-01 2001-08-28 Vista Scientific Llc Mucin containing ophthalmic preparations
US6520936B1 (en) * 1999-06-08 2003-02-18 Medtronic Minimed, Inc. Method and apparatus for infusing liquids using a chemical reaction in an implanted infusion device
US20040028655A1 (en) * 1999-08-06 2004-02-12 Nelson Kevin D. Drug releasing biodegradable fiber for delivery of therapeutics
US6669950B2 (en) * 1999-10-21 2003-12-30 Alcon, Inc. Ophthalmic drug delivery device
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6264971B1 (en) * 1999-11-04 2001-07-24 Btg International Limited Ocular insert
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6719750B2 (en) * 2000-08-30 2004-04-13 The Johns Hopkins University Devices for intraocular drug delivery
US6852106B2 (en) * 2000-12-14 2005-02-08 Control Delivery Systems, Inc. Implantable refillable and ported controlled release drug delivery device
US20020103412A1 (en) * 2001-02-01 2002-08-01 William Trimmer Micro pump
US20020188282A1 (en) * 2001-02-13 2002-12-12 Robert Greenberg Implantable drug delivery device
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US20030069560A1 (en) * 2001-05-03 2003-04-10 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US20030014036A1 (en) * 2001-06-12 2003-01-16 Varner Signe Erickson Reservoir device for intraocular drug delivery
US20030064088A1 (en) * 2001-08-29 2003-04-03 Carvalho Ricardo Azevedo Pontes De Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
US20030141618A1 (en) * 2001-11-30 2003-07-31 Cambridge Polymer Group, Inc. Layered aligned polymer structures and methods of making same
US20050175708A1 (en) * 2002-05-02 2005-08-11 Carrasquillo Karen G. Drug delivery systems and use thereof
US20040143221A1 (en) * 2002-12-27 2004-07-22 Shadduck John H. Biomedical implant for sustained agent release
US20060167435A1 (en) * 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
US20040199130A1 (en) * 2003-04-03 2004-10-07 Chornenky Victor I. Apparatus and method for treatment of macular degeneration
US20050187515A1 (en) * 2004-02-19 2005-08-25 Advanced Neuromodulation Systems, Inc. Reduced size programmable drug pump
US7276050B2 (en) * 2004-03-02 2007-10-02 Alan Franklin Trans-scleral drug delivery method and apparatus
US20060259015A1 (en) * 2005-05-10 2006-11-16 Palion Medical Corporation Implantable pump with infinitely variable resistor
US20070112328A1 (en) * 2005-05-10 2007-05-17 Palyon Medical Corporation Variable flow infusion pump system
US20060258994A1 (en) * 2005-05-12 2006-11-16 Avery Robert L Implantable delivery device for administering pharmacological agents to an internal portion of a body
US20070021735A1 (en) * 2005-07-15 2007-01-25 Sai Bhavaraju Dual membrane electro-osmotic fluid delivery device
US20080039792A1 (en) * 2006-03-14 2008-02-14 Ellis Meng Mems device and method for delivery of therapeutic agents
US20070255261A1 (en) * 2006-04-27 2007-11-01 Haase James M Infusion device with active and passive check valves
US20070255235A1 (en) * 2006-04-28 2007-11-01 Olsen James M Septum monitoring system and method for an implantable therapeutic substance delivery device

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110144617A1 (en) * 2006-03-14 2011-06-16 The University Of Southern California Mems device and method for delivery of therapeutic agents
US20110144619A1 (en) * 2006-03-14 2011-06-16 The University Of Southern California Mems device and method for delivery of therapeutic agents
US9693894B2 (en) 2006-03-14 2017-07-04 The University Of Southern California MEMS device and method for delivery of therapeutic agents
US8764708B2 (en) 2006-03-14 2014-07-01 The University Of Southern California MEMS device and method for delivery of therapeutic agents
US8308686B2 (en) 2006-03-14 2012-11-13 The University Of Southern California MEMS device and method for delivery of therapeutic agents
US20100305550A1 (en) * 2006-03-14 2010-12-02 Ellis Meng Mems device and method for delivery of therapeutic agents
US9308124B2 (en) 2007-12-20 2016-04-12 University Of Southern California Apparatus and methods for delivering therapeutic agents
US10117774B2 (en) 2007-12-20 2018-11-06 University Of Southern California Apparatus and methods for delivering therapeutic agents
US9271866B2 (en) 2007-12-20 2016-03-01 University Of Southern California Apparatus and methods for delivering therapeutic agents
US20130289482A1 (en) * 2008-01-03 2013-10-31 Ellis Fan-chuin Meng Implantable drug-delivery devices, and apparatus and methods for refilling the devices
US9901687B2 (en) * 2008-01-03 2018-02-27 University Of Southern California Implantable drug-delivery devices, and apparatus and methods for refilling the devices
US10850118B2 (en) 2008-01-07 2020-12-01 Salutaris Medical Devices, Inc. Methods and devices for minim ally-invasive delivery of radiation to the eye
US8430804B2 (en) 2008-01-07 2013-04-30 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye
US9873001B2 (en) 2008-01-07 2018-01-23 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US10022558B1 (en) 2008-01-07 2018-07-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US9056201B1 (en) 2008-01-07 2015-06-16 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US8597169B2 (en) 2008-01-07 2013-12-03 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye
US9333297B2 (en) 2008-05-08 2016-05-10 Minipumps, Llc Drug-delivery pump with intelligent control
US9162024B2 (en) 2008-05-08 2015-10-20 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9107995B2 (en) 2008-05-08 2015-08-18 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9199035B2 (en) 2008-05-08 2015-12-01 Minipumps, Llc. Drug-delivery pumps with dynamic, adaptive control
US9623174B2 (en) 2008-05-08 2017-04-18 Minipumps, Llc Implantable pumps and cannulas therefor
US20110202032A1 (en) * 2008-05-08 2011-08-18 Jason Shih Drug-delivery pumps with dynamic, adaptive control
US9987417B2 (en) 2008-05-08 2018-06-05 Minipumps, Llc Implantable drug-delivery devices, and apparatus and methods for filling the devices
US9283322B2 (en) 2008-05-08 2016-03-15 Minipumps, Llc Drug-delivery pump with dynamic, adaptive control
US9849238B2 (en) 2008-05-08 2017-12-26 Minipumps, Llc Drug-delivery pump with intelligent control
US9861525B2 (en) 2008-05-08 2018-01-09 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US20150038941A1 (en) * 2008-08-13 2015-02-05 Smed-Ta/Td, Llc Drug delivery implants
US9561354B2 (en) * 2008-08-13 2017-02-07 Smed-Ta/Td, Llc Drug delivery implants
USD691270S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to an eye
USD691268S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to eye
USD691269S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to an eye
USD691267S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to eye
US8808727B2 (en) 2009-01-29 2014-08-19 Forsight Vision4, Inc. Posterior segment drug delivery
US10813788B2 (en) 2009-01-29 2020-10-27 Forsight Vision4, Inc. Implantable therapeutic device
US8277830B2 (en) 2009-01-29 2012-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US8795712B2 (en) 2009-01-29 2014-08-05 Forsight Vision4, Inc. Posterior segment drug delivery
US9417238B2 (en) 2009-01-29 2016-08-16 Forsight Vision4, Inc. Posterior segment drug delivery
US10656152B2 (en) 2009-01-29 2020-05-19 Forsight Vision4, Inc. Posterior segment drug delivery
US11642310B2 (en) 2009-01-29 2023-05-09 Forsight Vision4, Inc. Posterior segment drug delivery
US8298578B2 (en) 2009-01-29 2012-10-30 Forsight Vision4, Inc. Posterior segment drug delivery
US9222819B2 (en) 2009-02-20 2015-12-29 University Of Southern California Tracking and controlling fluid delivery from chamber
US20110303016A1 (en) * 2009-02-24 2011-12-15 University Of Southern California Flexible polymer-based encapsulated-fluid devices
US8608632B1 (en) 2009-07-03 2013-12-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US8602959B1 (en) 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
US11679027B2 (en) 2010-08-05 2023-06-20 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10265215B2 (en) 2010-08-05 2019-04-23 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US11786396B2 (en) * 2010-08-05 2023-10-17 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
WO2012027435A3 (en) * 2010-08-24 2012-06-07 Qwtip Llc System and method for separating fluids and creating magnetic fields
WO2012027435A2 (en) * 2010-08-24 2012-03-01 Qwtip Llc System and method for separating fluids and creating magnetic fields
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US11065151B2 (en) 2010-11-19 2021-07-20 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9603997B2 (en) 2011-03-14 2017-03-28 Minipumps, Llc Implantable drug pumps and refill devices therefor
US10286146B2 (en) 2011-03-14 2019-05-14 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9919099B2 (en) 2011-03-14 2018-03-20 Minipumps, Llc Implantable drug pumps and refill devices therefor
US11813196B2 (en) 2011-06-28 2023-11-14 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US20130023813A1 (en) * 2011-07-19 2013-01-24 Abbott Cardiovascular Systems, Inc. Drug Delivery Device and Method
US8815278B2 (en) * 2011-07-19 2014-08-26 Abbott Cardiovascular Systems Inc. Drug delivery device and method
US9474832B2 (en) 2011-07-19 2016-10-25 Abbott Cardiovascular Systems Inc. Drug delivery device and method
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
WO2013040247A3 (en) * 2011-09-16 2013-05-10 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US10653554B2 (en) 2011-09-16 2020-05-19 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US11510810B2 (en) 2013-03-28 2022-11-29 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10850045B2 (en) 2014-04-03 2020-12-01 Toppan Printing Co., Ltd. Puncture injection instrument
US10363255B2 (en) 2014-08-08 2019-07-30 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10765677B2 (en) 2014-08-08 2020-09-08 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10575765B2 (en) 2014-10-13 2020-03-03 Glusense Ltd. Analyte-sensing device
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US11110001B2 (en) 2014-11-10 2021-09-07 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US9763825B2 (en) * 2015-09-11 2017-09-19 California Institute Of Technology Implantable oxygen generator and transporter
US20170071785A1 (en) * 2015-09-11 2017-03-16 California Institute Of Technology Implantable oxygen generator and transporter
US10342698B2 (en) * 2015-09-11 2019-07-09 California Institute Of Technology Implantable oxygen generator and transporter
US20170100598A1 (en) * 2015-10-13 2017-04-13 Glusense Ltd. Implant illumination
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US10871487B2 (en) 2016-04-20 2020-12-22 Glusense Ltd. FRET-based glucose-detection molecules
USD814637S1 (en) 2016-05-11 2018-04-03 Salutaris Medical Devices, Inc. Brachytherapy device
USD814638S1 (en) 2016-05-11 2018-04-03 Salutaris Medical Devices, Inc. Brachytherapy device
USD815285S1 (en) 2016-05-11 2018-04-10 Salutaris Medical Devices, Inc. Brachytherapy device
USD808528S1 (en) 2016-08-31 2018-01-23 Salutaris Medical Devices, Inc. Holder for a brachytherapy device
USD808529S1 (en) 2016-08-31 2018-01-23 Salutaris Medical Devices, Inc. Holder for a brachytherapy device
US10946182B2 (en) 2017-03-07 2021-03-16 Medi Tulip Co., Ltd. Subcutaneous vein access port and medicine injection device having the same
US10492945B2 (en) 2017-05-22 2019-12-03 California Institute Of Technology Small molecule transport device with anti-condensation filler for drug delivery or waste removal
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
CN111655206A (en) * 2017-11-21 2020-09-11 弗赛特影像4股份有限公司 Fluid exchange device for expandable port delivery system and method of use
US11351057B2 (en) * 2018-09-17 2022-06-07 Alcon Inc. Low friction trocar valve

Also Published As

Publication number Publication date
EP2727616A1 (en) 2014-05-07
ES2577502T3 (en) 2016-07-15
MX2010007382A (en) 2010-12-20
JP5798159B2 (en) 2015-10-21
EP2240220B1 (en) 2016-04-13
PL2240220T3 (en) 2016-09-30
EP2266643A3 (en) 2011-03-30
WO2009089094A2 (en) 2009-07-16
EP2266643A2 (en) 2010-12-29
WO2009089094A3 (en) 2009-09-03
EP2240220A2 (en) 2010-10-20
ES2546192T3 (en) 2015-09-21
EP2727616B1 (en) 2017-04-26
WO2009089094A8 (en) 2009-10-22
JP2014028145A (en) 2014-02-13
EP2266643B1 (en) 2015-06-17
DK2240220T3 (en) 2016-08-01
US20130289482A1 (en) 2013-10-31
US9901687B2 (en) 2018-02-27
JP2011509120A (en) 2011-03-24

Similar Documents

Publication Publication Date Title
US9901687B2 (en) Implantable drug-delivery devices, and apparatus and methods for refilling the devices
AU2015230874B2 (en) Methods and devices for drug delivery to ocular tissue using microneedle
US20080058704A1 (en) Apparatus and Method for Ocular Treatment
JP4505219B2 (en) Methods and devices for subretinal drug delivery
EP2193821A1 (en) Apparatus for ocular treatment
US10286146B2 (en) Implantable drug pumps and refill devices therefor
US9603997B2 (en) Implantable drug pumps and refill devices therefor
CN105979914B (en) System and method for being delivered under the retina of therapeutic agent
US20030135153A1 (en) Drug implant injection device
US20080140024A1 (en) Drug delivery device
CN105902341B (en) Medicine-filling device under Tenon capsule
JP4974884B6 (en) Equipment for eye treatment
WO2022180513A1 (en) Advanced cochlea access

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF SOUTHERN CALIFORNIA, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MENG, ELLIS;HUMAYUN, MARK;LO, RONALEE;AND OTHERS;REEL/FRAME:022550/0763

Effective date: 20090224

AS Assignment

Owner name: NATIONAL SCIENCE FOUNDATION, VIRGINIA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF SOUTHERN CALIFORNIA;REEL/FRAME:023030/0523

Effective date: 20090331

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION